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Abstract 
 Cerebrospinal fluid (CSF) biomarkers of neurodegenerative 
diseases have a wide scope of applications in diagnostics, prognosis 
assessment, disease staging, treatment evaluation and more. In this PhD 
project we aimed to expand the understanding of the properties of 
known CSF biomarkers of Alzheimer’s disease (AD) and other 
neurodegenerative diseases, including the most prevalent dementia 
disorders. 
 In study I, we explored CSF concentrations of three hallmark 
biomarkers of AD (amyloid β 1-42 [Aβ1-42], total tau [T-tau] and 
phosphorylated tau [P-tau]) in samples collected in clinical routine from 
5676 patients. We found that the most clear-cut AD-like biomarker 
pattern was found in patients diagnosed with AD, but that large 
proportions of patients with other dementia disorders also had an AD-
like profile. However, this was less often seen in the frontotemporal 
dementia (FTD) group. 
 In study II, we studied CSF concentrations of neurofilament light 
(NfL), a biomarker of general neurodegeneration, in 3356 patients with 
different dementia diagnoses. We found that CSF NfL is especially high 
in dementias with vascular engagement, but also in frontotemporal 
dementia. We also found that high CSF NfL concentrations are linked to 
short survival, which supports the notion that high CSF NfL indicates 
more aggressive disease processes. 
 In study III, the biomarkers T-tau and P-tau were evaluated as 
biomarkers of Creutzfeldt-Jakob disease (CJD), a rare rapid 
neurodegenerative disease. We could conclude that the combination of 
increased T-tau levels and increased T-tau/P-tau ratios in patients with 
CJD has a very high specificity against important differential diagnoses to 
CJD. We further concluded that CJD patients exhibit rising T-tau 
concentrations as the disease progresses.  
 In study IV, we developed a new strategy for analyzing data 
output from explorative mass spectrometry. We used a clustering 
algorithm to allow for higher efficiency and were able to prove the 
validity of this concept by identifying and validating a new biomarker of 
AD, a 16 amino acids long peptide from the protein pleiotrophin 
(PTN151-166). We concluded that quantification-driven proteomics aided 
by clustering is a viable way of hypothesis generation in biomarker 
discovery studies. We further concluded that PTN151-166 is a promising 
AD biomarker candidate that our data indicates to be AD specific and 
able to discriminate AD from other dementia pathologies at an early 
stage of disease. 
 In conclusion, the results from the studies in this thesis 
demonstrate the diagnostic, prognostic and investigative properties of 
CSF biomarkers. 
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Populärvetenskaplig 
sammanfattning 
Demenssjukdomar är vanliga och är på väg att bli ännu mer 
vanliga. Detta beror främst på att sociala, ekomomiska och medicinska 
framsteg har gjort att vi blir allt äldre. Denna utveckling är naturligtvis 
glädjande, men baksidan är att åldersrelaterade sjukdomar, såsom 
demenssjukdomar, blir vanligare. Stora resurser har lagts på att utveckla 
läkemedel mot demenssjukdomar under de senaste decennierna, men 
besvikelserna har varit många. Det finns ännu ingen bot eller effektiv 
behandling mot någon demenssjukdom. Studierna i denna avhandling är 
inriktade på att undersöka så kallade biomarkörer för demenssjukdomar. 
Biomarkörer är substanser eller egenskaper hos en individ som indikerar 
förekomst av ett tillstånd eller en sjukdom. Biomarkörer kan t.ex. 
användas i den kliniska vardagen för att avgöra om någon har en viss 
sjukdom, eller i en läkemedelsstudie för att avgöra om en nyutvecklad 
medicin har effekt på en sjukdom. Syftet med studierna i denna 
avhandling har varit att öka kunskapen om biomarkörer för 
demenssjukdomar.  
I de två första studierna i denna avhandling sammankopplade vi 
det svenska demensregistret (Svedem) med laboratoriedatabasen på 
Sahlgrenska sjukhuset. Genom detta kunde vi samla tusentals mätningar 
av biomarkörer relaterade till den vanligaste demenssjukdomen, 
Alzheimer’s sjukdom (Aβ1-42, T-tau och P-tau), och allmän nervcellsdöd 
(NfL). I den första studien fann vi i en population omfattande 5676 
individer att biomarkörerna Aβ1-42, T-tau och P-tau tillsammans utmärker 
Alzheimer’s sjukdom från andra demenser, men att förhöjda nivåer av 
dessa markörer ofta kan ses även i andra demenssjukdomar. I den andra 
studien, som innefattade en population om 3356 individer, såg vi att 
markören NfL är förhöjd i alla demenssjukdomar representerade i vårt 
material jämfört med friska kontroller, samt att patienter med höga 
nivåer av denna biomarkör hade kortare överlevnad. 
I den tredje studien undersökte vi två varianter av proteinet tau 
(T-tau och P-tau) som biomarkörer för den ovanliga och snabbt 
framskridande demensen Creutzfeldt-Jakobs sjukdom. Vi fann att 
patienter med denna sjukdom hade mycket höga nivåer av tau och att 
detta effektivt kunde skilja dem från patienter med andra 
demenssjukdomar. Vidare fann vi allt högre nivåer i patienter ju längre 
sjukdomen framskred, vilket tyder på att nervcellsdöden i Creutzfeldt-
Jakobs sjukdom accelerar med tiden, och att tau kan användas för att 
mäta sjukdomens intensitet. 
Den fjärde studien syftade till att leta nya biomarkörer för 
Alzheimer’s sjukdom. Vi utvecklade ett nytt sätt att analysera data från 
mass spektrometri. Mass spektrometri är en teknik som kan användas för 
att analysera protein-innehållet i t.ex. cerebrospinalvätskan, dvs den 
vätska som omger hjärnan. Med den nya metoden kunde vi ta vara på 
den stora mängd data som produceras vid en sådan analys på ett mycket 
effektivare sätt än vad som tidigare varit möjligt. Vi kunde även bevisa att 
den nya metoden fungerade genom att identifiera och validera en helt ny 
och tidigare okänd biomarkör för Alzheimer’s sjukdom, PTN151-166. 
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Abbreviations 
AChE Acetylcholineesterase 
AD  Alzheimer's disease 
ADAD Autosominal dominant Alzheimer’s disease 
ADAS-Cog Alzheimer's Disease Assessment Scale-cognitive subscale 
AICD APP intracellular domain 
APP Amyloid precursor protein 
AUC Area under the curve 
Aβ Amyloid β 
Aβ1-40 Amyloid β amino acid sequence 1-40 
Aβ1-42 Amyloid β amino acid sequence 1-42 
BBB Blood-brain-barrier 
bvFTD Behavioural variant FTD 
CBD Corticobasal degeneration 
CID Collision induced dissociation 
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DLB Dementia with Lewy bodies 
EAD  Early onset Alzheimer’s disease 
ELISA Enzyme linked immunosorbent array 
ESI Electrospray ionisation 
FDA Federal drugs administration 
FTLD Frontotemporal lobar degeneration 
FTD Frontotemporal dementia 
FTD-MND Frontotemporal dementia with motor neuron disease 
FTDP-17 Frontotemporal dementia and parkinsonism linked to chromosome 17 
FUS Fused in sarcoma 
HPLC High pressure/performance liquid chromatography 
HSV-1 Herpes simplex virus 1 
ICD-10 International Statistical Classification of Diseases and Related Health 
IWG International working group  
LAD Late onset Alzheimer’s disease 
LC Liquid chromatography 
LRP LDL receptor-related protein 
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LP Lumbar puncture 
m/z Mass-to-charge-ratio 
MALDI Matrix-assisted laser desorption/ionisation 
MAPT Microtubule-associated protein tau 
MCI Mild cognitive impairment 
MMSE Mini mental state examination 
MND Motor neuron disease 
MRI Magnetic resonance imaging 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
Nf(L/M/H) Neurofilament [light/medium/heavy] chain 
NFT Neurofibrillary tangle 
nfvPPA Nonfluent variant primary progressive aphasia 
Ng Neurogranin 
NIA-AA US National Institute on Aging-Alzheimer’s Association 
ROC Receiver Operating Characteristics 
PD Parkinson's disease 
PDD Parkinson’s disease dementia 
PET Positron emission tomography 
PRM Parallel reaction monitoring 
PSP Progressive supranuclear palsy 
P-tau Total concentration of phosphorylated protein tau 
PTN Pleiotrophin 
PTN151-166 Pleiotrophin amino acid sequence 155-166 
PTPRZ Chondroitin sulfate proteoglycan receptor-type protein tyrosine 
SAD Sporadic Alzheimer’s disease 
SRM Single reaction monitoring 
SSRI Selective serotonin reuptake inhibitor 
sPDGFRβ Platelet-derived growth factor receptor-β 
SPECT Single photon emission computer tomography 
svPPA Semantic variant of primary progressive aphasia 
TBI Traumatic brain injury  
TDP-43 TAR DNA-binding protein 43 
TMT Tandem Mass Tag 
T-tau Total concentration of protein tau 
VaD Vascular dementia 
YKL-40 Chitinase-3-like protein 1 
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“Excessive reservations and paralyzing despondency have not helped the sciences to 
advance nor are they helping them to advance, but a healthy optimism that cheerfully 
searches for new ways to understand, as it is convinced that it will be possible to find 
them.” 
Alois Alzheimer 
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Introduction 
 
 
Neurodegenerative disease and dementia 
teady progress across several areas including medicine, 
technology and economy has helped increase living standards 
and life expectancies across the globe over the past 70 years [1-3]. 
This undeniably positive development has however brought new 
challenges as decreased mortality rates are followed by a growing elderly 
population, and a growing incidence of age-related disease [4]. One of 
the disease groups that have seen such an incidence surge is dementia, 
leading to the fear of a growing dementia epidemic being discussed in the 
field of dementia research around the world [5-7].  
Primary concepts 
Dementia is a syndrome and a general term describing a group of 
pathologic disorders with the common denominator of permanent 
S
decline in the patients’ cognitive and functional abilities [8]. Dementia 
symptoms may arise in a variety of different disorders characterized by 
many pathological processes. The most common symptom associated 
with dementia is short term memory loss, but dementia symptomatology 
is broad and can include many different cognitive, behavioral or 
emotional symptoms including impairment in communication, language 
and visual perception, focus and attention, difficulties with reasoning and 
judgment, anxiety and depression. The symptom spectra of the different 
dementia disorders vary greatly. Dementias result in severe suffering for 
the affected patient and relatives, and are generally progressive and lead 
to increasing disability and ultimately death. Alzheimer’s disease (AD), 
the most common dementia disorder, is often called a family disease due 
to the tremendous toll it takes on the relatives watching the personality 
of a spouse, parent, sister, brother or friend slowly fade away. 
Age is the most important risk factor for developing most 
dementia disorders [9]. Some studies suggest that the dementia risk might 
be decreasing among older adults due to a number of factors, such as 
better cardiovascular prevention and healthier lifestyles, leading to lower 
risks of developing vascular dementia and higher education levels 
generating better cognitive reserves [10-12]. However, the overall 
prevalence of dementia is still expected to grow rapidly in the ageing 
world population [4]. Additionally, there are currently no disease-
modifying treatments available for any of the most prevalent dementia 
disorders. In sum, dementia is a growing health concern and is projected 
to pose a great social and economic burden in the relatively near future 
[13, 14]. 
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Alzheimer’s disease (AD) 
Alzheimer’s disease is named after the German psychiatrist and 
neuropathologist Alois Alzheimer (1864-1915), who met a 51-year-old 
patient with memory-loss and behavioral symptoms at the Frankfurt 
asylum in 1901. Her name was Auguste Deter. He was intrigued by her 
symptoms and observed her over the following years. When she died 
five years later he had her brain neuropathologically examined. He found 
it atrophied and riddled with protein aggregates (later dubbed amyloid 
plaques and neurofibrillary tangles, collectively referred to as “AD 
pathology” below), and described his findings at meetings and in papers 
over the following years, although initially failing to spark much attention 
within the scientific community [15, 16]. However, interest slowly caught 
on in the following years and in 1910 his mentor Emil Kraepelin coined 
the name Alzheimer’s disease and described the syndrome in the 8th 
edition of his Handbook of psychiatry.  
AD is now known to be the most common form of dementia, 
accounting for approximately 60 – 70 % of all dementia cases [17]. AD is 
mainly a disease of the aging brain and has a marked increase in 
incidence with a doubling every fifth year after the age of 65. The 
approximate prevalence of AD in a population over 60 years old is 5 % 
[18]. AD pathology affects the cerebral cortex and certain subcortical 
regions. The entorhinal cortex and hippocampus are affected early on in 
the disease process leading to the most characteristic symptom of AD, 
short term memory loss. Though the majority of AD cases are sporadic 
and have a late onset, a small minority of AD patients have causative 
genetic mutations. This form of the disease is called autosomal dominant 
AD (ADAD) and often manifests clinically as early-onset AD (defined as 
AD with symptom onset before 65 year of age). Most AD patients lack 
such dominant mutations, and are therefore said to have a sporadic form 
of the disease (SAD). Most patients with SAD have late onset of 
symptoms, after 65 years of age, although SAD can also debut early, and 
most early-onset patients do not have ADAD.  
The amyloid cascade hypothesis  
AD pathology is characterized by an accumulation of 
extracellular plaques in the brain, containing the aggregated form of the 
amyloid β (Aβ) peptide, and intraneuronal neurofibrillary tangles (NFTs) 
consisting of aggregates of the hyperphosphorylated form of the tau 
protein [19, 20]. Following the identification of Aβ and the genetic 
variants linked to autosomal dominant forms of the disease (all in genes 
involved in Aβ metabolism), the amyloid cascade hypothesis was introduced 
stating that an imbalance in the production or clearance of Aβ is the 
instigating event in AD leading to subsequent formation of amyloid 
plaques, tau tangles, oxidative stress, and microglial activation resulting in 
neuronal death (figure 1) [21, 22]. While there are other hypotheses for 
the underlying pathological mechanisms of AD (discussed in a later 
section), the amyloid cascade hypothesis is the most prominent and one 
that has sparked extensive research into the cause of abnormal 
production and clearance of Aβ peptides, and especially the highly 
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aggregation prone and 
potentially toxic 42 amino 
acid long Aβ peptide (Aβ1-
42), and the development of 
drugs targeting the 
production, aggregation 
and clearance of Aβ 
peptides [23-25]. Aβ1-42 is 
the main component of 
amyloid plaques in AD. 
Different lengths of Aβ 
peptides are cleaved from the membrane embedded amyloid precursor 
protein (APP) by the enzymes β- and γ-secretase. In AD, shedding of Aβ 
is for unknown reasons shunted into more Aβ1-42 (rather than shorter 
isoforms including Aβ1-40), which appears to lead to amyloid plaque 
build-up [26]. Amyloid plaque accumulation precedes the formation of 
wide-spread NFTs in AD, but the link between the two remains to be 
explained. Unproven theories postulate that Aβ might induce 
phosphorylation of tau by directly altering the phosphorylation of tau,  
by interacting with APP or by inducing kinases to modify tau [27]. 
 
The amyloid cascade hypothesis is backed up by several lines of 
evidence. The brains of AD patients’ exhibit hallmark post-mortem 
signs: amyloid plaques, NFTs and atrophy. Studies of ADAD have 
shown that mutations in the amyloid precursor protein gene (APP), or in 
the presenilin-1 (PSEN1) and presenilin-2 genes (PSEN2), the key 
Figure 1. The amyloid cascade hypothesis schematic. 
catalytic subunits of –secretase, cause AD [28, 29]. Transgenic mice 
expressing familial human APP and PSEN mutations also develop 
syndromes that mirror certain aspects of AD [30]. But there are also 
challenges to the amyloid cascade hypothesis [31]: 
 At autopsy about 20-40% of cognitively intact elderly subjects 
meet some neuropathological criteria for AD, and in CSF 
biomarker or PET imaging studies in cognitively healthy 
individuals, biomarker signs of Aβ deposition increase with age 
and is particularly elevated in about 20% of adults aged 60 and 
over [32, 33]. This is not readily reconciled with the notion of Aβ 
aggregates as the instigating factor in AD [26, 34, 35].  
 Amyloid plaque and NFT burden and clinical measures of 
cognitive health does generally not correlate well [32, 35]. If 
amyloid and tangles are the sole cause of neurodegeneration in 
AD, this correlation should be clear. 
 Drug trials targeting the obvious culprit in the amyloid cascade 
paradigm, i.e. Aβ aggregates and associated proteins, have 
broadly failed. Although having in several cases successfully 
cleared Aβ plaques and shown signs of reversing AD symptoms 
in mice, these properties have not translated well into human 
treatments [36]. Some treatments have shown effects on Aβ 
pathology in humans but nonetheless been unsuccessful in 
stopping cognitive decline or neurodegeneration [37-39]. Roche’s 
anti Aβ antibody gantenerumab removed Aβ plaques in patients 
to mean levels below 24 centiloid (a radiological threshold for 
evidence of Aβ pathology) in 1-2 years, but still failed to halt 
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cognitive decline [40]. When writing this, the news of another 
failed drug trial has just been released. In 2016, study results from 
a phase 1B study were published that showed that aducanumab 
reduced Aβ plaque load and indicated better cognitive results in 
treated patients; but the subsequent phase III has now been shut 
down due to falling short of their primary endpoint [37, 41]. 
 Brainstem and medial temporal lobe NFTs are seen in subjects 
without Aβ depositions in all age categories, which don’t seem to 
support the idea of Aβ plaque formation as an upstream feature 
of AD pathogenesis [42, 43].  
 Aβ is expressed fairly equally throughout the AD brain, while 
neurodegeneration initially affects specific parts of the brain, 
namely the hippocampus and entorhinal cortex (figure 2) [44]. 
This phenomenon is not explained by the amyloid cascade 
hypothesis. 
 Although Aβ build up is clearly an important feature of AD-like 
pathology, the exact biochemical mechanisms for the 
propagation of the adverse effects of Aβ remain elusive [45].  
 Amyloid plaques and NFTs can occur alone in some disorders. 
NFTs develop without the presence of amyloid plaques in tangle-
only dementia, and amyloid plaques accumulate without 
subsequent NFTs in hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type [46, 47]. While this doesn’t directly 
contradict the validity of the amyloid cascade hypothesis, it 
suggests a complex relationship between amyloid plaques and 
NFTs that remain to be elucidated. Further, transgenic mice 
harboring the APP or PSEN mutations develop Aβ plaques, but 
not NFTs [48]. 
 
 
Figure 2. Propagation of pathology in the brain of AD patients follows a defined pattern. Aβ 
plaque pathology (top row) engages cerebral regions relatively uniformly and subsequently 
propagates to deeper regions, while NFTs (bottom row) initially build up in the entorhinal cortex 
and from there spread to cerebral regions as the disease progresses. 
Alternative hypotheses of AD pathology 
 In spite of the above mentioned weaknesses, the amyloid cascade 
hypothesis might still be valid after some tweaking, or to explain 
heritable AD. Being designed after findings in animal models of ADAD, 
it might be the assumption that the hypothesis can be extrapolated onto 
all AD that is not accurate. This is the case in other diseases, for example 
skin blistering disorders, where early- and late-onset forms clinically 
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resemble each other but have different etiological bases. Early-onset 
forms (epidermolysis) have a genetic basis, while late-onset forms 
(pemphigoids) are autoimmune diseases, leaving widely different options 
for treatment of the two forms [49]. Diabetes type I and II are also 
examples of diseases with common symptomatology, but different 
etiology. 
 Alois Alzheimer noted another histopathological hallmark of AD 
that has not garnered nearly as much attention as the others: lipoid 
granules [50]. The identification of APOE as the strongest genetic risk 
factor of AD points to a link between lipid metabolism and AD, as 
APOE is a regulator of cholesterol metabolism in the CNS. 
Epidemiological studies also support a role of cholesterol in AD 
pathogenesis [51]. Statin treatment in animal models leads to decreased 
levels of Aβ, and retrospective epidemiological studies have suggested a 
reduced risk of AD in statin treated patients [52]. Physiological 
differences in plasma lipid metabolism could also explain the higher 
incidence of AD in women [53]. Lipids might regulate the pathogenic 
potential of other agents by regulating cell membrane integrity, and could 
also influence the aggregation of these agents. Growing evidence suggest 
that the amyloidogenic processing of APP occur mainly in so called lipid 
rafts, lipid rich membrane domains that cluster receptors and signaling 
molecules [54]. In a scenario where changes in lipid metabolism is the 
instigating factor in AD pathogenesis, Aβ-aggregation would merely be a 
side effect due to increased occurrence of lipid rafts in cell membranes, 
which in turn would explain the lack of success of drugs targeting Aβ-
plaques, BACE1 and Aβ oligomers. 
 Evidence have also been put fourth that support a major role of 
contagions in AD pathogenesis. Herpes simplex 1 (HSV-1) encephalitis 
primarily affects the entorhinal cortex and the hippocampus, the same 
anatomical regions where neurofibrillary tangles gain foothold [55]. 
Further, HSV-1 kinase has been implicated in tau hyperphosphorylation, 
and neuropathological studies have shown a strong correlation between 
the presence of HSV-1 DNA in human brains and the likelihood of AD 
[55, 56]. Reactivated HSV-1 in the brains of elderly and more susceptible 
brains could be the trigger factor in AD pathogenesis. In this theory, 
again, Aβ and tau aggregation would only be side effects of another 
pathological process. Other pathogens have also been implicated in AD 
pathogenesis. Recently, toxic proteases from the bacteria Porphyromonas 
gingivalis, a common oral pathogen, were identified in the brains of AD 
patients, and found to correlate with tau pathology, and P. gingivalis 
infection in mice resulted in increased production of intracerebral Aβ1-42 
[57]. 
Diagnosis and diagnostic challenges 
A definitive diagnosis of AD cannot be reached without post-
mortem neuropathological examination of the patients’ brain. Due to 
practical limitations to this method, diagnostic criteria and tools have 
been developed to aid diagnostics in clinical practice and research. 
According to ICD-10 criteria [58], AD is characterized by: 
A. The development of multiple cognitive deficits manifested by 
both: 
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1. Memory impairment 
2. One or more of: 
a) Aphasia 
b) Apraxia 
c) Agnosia 
d) Disturbance in executive functioning 
B. Cognitive deficits in A1 and A2 each cause significant 
impairment in social functioning. 
C. Symptoms appear with gradual onset and continuing decline. 
D. Symptoms in A1 and A2 cannot be explained by other 
diseases or substance-intake. 
E. Symptoms do not occur exclusively during delirium. 
F. Symptoms cannot be better be explained by depression, 
schizophrenia or similar conditions. 
The National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria is also commonly used [59].  
In the research setting, The International Working Group (IWG) 
has put forward diagnostic criteria for AD, which were updated in 2014 
and dubbed the IWG-2 criteria [60, 61]. In the new revision 
neurochemical and neuroimaging diagnostic markers were introduced. 
Low concentrations of Aβ1-42 and high concentrations of total tau (T-tau) 
and phosphorylated tau (P-tau) in the cerebrospinal fluid (CSF) indicate 
plaque pathology and neuronal damage respectively. Increased tracer 
retention of amyloid PET is also considered in vivo evidence of AD 
pathology. The IWG-2 criteria are as of yet mainly recommended for 
research purposes and CSF and imaging biomarkers are thus not yet fully 
implemented in diagnostic criteria for the clinical setting. However, many 
European countries, including Germany, have recently issued 
recommendations to include CSF biomarkers as a supplement to clinical 
evaluation in dementia diagnostics [62, 63]. 
Diagnostics in AD and dementia in general can be challenging. 
Cognitive decline is a progressive and often slow process, and it can be 
difficult to distinguish specific traits in clinical presentations. Early 
diagnosis is especially challenging (and preclinical AD, prior to any 
symptoms, can by definition not be detected by clinical testing alone). 
Additionally, co-morbidities are common, blurring the lines between 
specific disorders. In post-mortem AD brains, Lewy body pathology 
associated with dementia with Lewy bodies (DLB) and Parkinson’s 
disease dementia (PDD) have been shown to occur in more than 50% of 
cases, and signs of vascular dementia might be even more common [64-
66]. Further, neither amyloid plaques nor neurofibrillary tangles are 
specific for AD [66-68]. NFTs are found in many other 
neurodegenerative diseases, such as prion disease, metabolic diseases, 
some brain tumors and also in cognitively normal aging subjects [42]. 
Amyloid plaques are, as previously mentioned, found in many cognitively 
intact elderly subjects, and are also prevalent in DLB and PDD [69]. 
Mixed pathologies and presence of subclinical pathologies in dementia 
lead to variations in both clinical presentation and uncertainties in 
biomarker read outs. 
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Current treatment of AD 
Despite the significant effort put into the search for disease 
modifying treatments of AD, none other than symptomatic treatments 
have as of yet been found [70]. There are two strategies of treating the 
symptoms of AD available today, the first being acetylcholineesterase 
(AChE) inhibitors like donepezil, galantamine or rivastigmine. By 
inhibiting the enzyme AChE, the rate of degradation of acetylcholine in 
the synaptic cleft is reduced, thus potentiating the level and duration of 
action of the neurotransmitter. The aim of this treatment is to slow 
cognitive decline and ease memory difficulties. Effects of the different 
agents in this group on the market are similar and generally considered 
moderate [70-72].  Response rates vary, and about one third of the 
patients experience no benefit, while one third doesn’t tolerate the 
treatment due to side effects [70]. 
The second strategy of AD treatment is to block NMDA 
receptors by NMDA receptor antagonists like memantine. The aim of 
this strategy is to hinder neuronal excitotoxicity and by that exert 
neuroprotection [73]. Memantine was first synthesized in the 60s and 
marketed as a potential diabetes treatment. The NMDA receptor 
blocking properties of the drug was first discovered and applied in AD 
treatment in the 1980s [74]. Memantine is generally better tolerated than 
AChE inhibitors and is especially used for treatment of AD patients that 
don’t tolerate or have contraindications for AChE inhibitor use, or 
patients with more than mild symptoms. Memantine might also have 
beneficial effects in combination with an AChE inhibitor [73]. However, 
although memantine therapy improve cognition and global function in 
AD, the efficacy is limited as is evidence of clinical benefit [75]. 
 
Vascular dementia (VaD) and mixed dementia 
VaD, the second most common dementia, accounts for about 10 
- 20% of all dementia cases. Subtypes of VaD include multi-infarct 
dementia, caused by series of minor ischemic or hemorrhagic strokes 
leading to stepwise cognitive decline; strategic infarct dementia, caused 
by ischemic lesions involving specific sites in the brain; and subcortical 
dementia, caused by small vessel disease leading to lacunar infarcts and 
diffuse white matter lesions [76, 77]. Symptoms of VaD vary depending 
of which regions of the brain are affected; Cortical lesions can cause 
aphasia, apraxia and epileptic seizures, while subcortical lesions lead to 
bradyphrenia, executive dysfunction, gait changes, urinary incontinence 
and parkinsonism [78]. VaD patients also often exhibit focal neurologic 
signs such as hemiparesis, bradykinesia or hyperreflexia. The clinical 
distinction between AD and VaD can be challenging, and AD and VaD 
pathologies often coexist in a condition called mixed dementia. 
Neuropathological studies indicate that this might be very common [79, 
80]. 
Management of VaD includes addressing risk factors of 
cardiovascular health, including tobacco use, hypertension, atrial 
fibrillation, diabetes and high cholesterol to provide protection against 
strokes and vascular pathology. As progress has been made in stroke and 
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vascular disease prevention over the last decades the incidence of VaD is 
declining [81]. 
 
Frontotemporal dementia (FTD) 
FTD is a group of clinical syndromes with a common feature of 
progressive neurodegeneration of mainly the frontal and anterior 
temporal lobes, leading to personality and behavioral changes or 
difficulties with language. FTD has a strong genetic component with 
about 40 % of cases having a family history of dementia, psychiatric 
disease or motor symptoms [82]. FTD also has an earlier onset than 
other dementias and symptoms usually occur in between ages 45 to 65 
[83].  FTD is commonly divided into three main subtypes: behavioral 
variant FTD (bvFTD) is the most common one accounting for about 
half of the FTD cases, while semantic variant of primary progressive 
aphasia (svPPA) and nonfluent variant primary progressive aphasia 
(nfvPPA) are rarer. BvFTD engage mainly the paralimbic areas including 
the medial frontal, orbital frontal, anterior cingulate and frontoinsular 
cortices [84]. Right hemisphere atrophy is associated more with behavior 
changes, and affected patients often display apathy, become socially 
withdrawn, rigid in their thinking and might behave socially 
inappropriate [85-87]. SvPPA and nfvPPA are characterized by anterior 
temporal lobe atrophy, and clinically feature language problems with loss 
of meaning of words in svPPA and problems with producing speech in 
nfvPPA [88, 89]. When the left temporal lobe is engaged, language 
functions are mostly impaired, and when the right temporal lobe is 
engaged the symptoms are mainly behavioral. Over time, both temporal 
lobes become affected, and subsequently also the frontal lobes leading to 
symptoms of bvFTD. Memory problems are not a key feature of FTD. 
There are also conditions that are considered closely related to FTD, and 
are collected under the frontotemporal lobar degeneration (FTLD) 
umbrella term, but engage partly different anatomical regions, including 
frontotemporal dementia with motor neuron disease (FTD-MND), 
progressive supranuclear palsy (PSP) and corticobasal degeneration 
(CBD). There is further a logopenic variant of PPA that has been 
correlated predominantly with AD pathology. 
As in AD, protein aggregation is a major pathological feature of 
FTD and FTLD. FTLD is sub classified according to 
immunohistochemical staining for specific protein accumulations into 
four main subtypes, each with several sub classifications of their own 
[90]. In FTLD-tau, like in AD, the protein tau is accumulated; although 
tau inclusions in FTLD-tau differ from AD in that they primarily contain 
one or two of the six tau isoforms and not all six. FTLD-tau can be 
divided into 4R tauopathies, including CBD, PSP, and 3R tauopathies, 
including Pick’s disease, depending on which isoform of tau is 
predominantly deposited. Pick’s disease clinically most commonly 
presents as bvFTD, but can sometimes also be seen as the nfvPPA or 
svPPA phenotypes [84]. Specific mutations in MAPT, the tau gene, cause 
dominantly inherited FTD and Parkinsonism linked to chromosome 17 
(FTDP-17) or familial FTLD-tau [91]. 
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FTLD-TDP is characterized by four types (A-D) of TAR DNA-
binding protein 43 (TDP-43) aggregation and related pathologic 
properties. TDP-43 is involved in mRNA processing, but its exact 
biological function is unknown. FTLD-TDP clinically typically presents 
as svPPA (type C), but bvFTD, nfvPPA and CBS can also be seen (type 
A, B). Aggregates of TDP-43 is also a main feature of motor neuron 
disease (MND), and mutations in the gene C90RF72 is the most 
common genetic cause of both FTD and MND [92]. Additionally, about 
10-15% of patients with FTD also subsequently develop MND (FTD-
MND) symptoms, and inversely about 50% of the patients that debut 
with MND later in the disease progression develop cognitive impairment 
and 15% meet criteria for FTD [93]. 
The third immunohistochemical sub classification of FTLD, 
FTLD-FET, account for 5-10 % of the total FTLD cases, a group that is 
both tau and TDP-43 negative. In 2009 links between the fused in 
sarcoma (FUS) gene and MND was found [94]. The known overlap of 
FTD and MND sparked an investigation of the relation between FTD 
and FUS, where FUS inclusions were found in FTD but mutations in 
FUS showed no link to FTD [95]. FUS is a member of the FET protein 
family, and an RNA/DNA binding protein just like TDP-43, implying 
abnormal RNA metabolism as an important event in FTLD-FET 
pathology. 
The fourth and last sub group of FTLD is FTLD-UPS, caused 
by a rare mutation in the CHMP2B gene found in a Danish family. 
FTLD-UPS exhibit inclusions of ubiquitin, but are negative for tau, 
TDP-43 and FET. 
There are no specific treatments of FTD, although symptoms 
might sometimes be relieved by antidepressants and antipsychotics [96]. 
The average survival time from diagnosis is between 3-12 years 
depending of which subpopulation of patients is studied; Patients with 
bvFTD and concomitant motor neuron disease average 3 years, while 
svPPA patients live 12 years from diagnosis on average [97]. 
  
Dementia with Lewy bodies (DLB) and Parkinson’s 
disease dementia (PDD) 
DLB and PDD are both characterized by the formation of α-
synuclein containing deposits in the brain and peripheral nervous system 
called Lewy bodies [69]. In both diseases Lewy bodies can be found in 
the frontal and temporal cortex, however, there is a higher cortical Lewy 
body load as well as more frequent and severe hippocampus and 
amygdala load in DLB [69]. There is also convergent influence of Aβ and 
tau pathology in both DLB and PDD, but higher degrees of Aβ and tau 
loads in the cortex and striatum can be seen in DLB [69].  
Both diseases feature impaired cognition, sleep disorders, visual 
hallucinations, depression and parkinsonism, i.e. muscular rigidity, 
bradykinesia, postural instability [98-101]. The distinguishing factor 
between the two disorders is the order in which symptoms appear. In 
PDD, a diagnosis of PD precedes the onset of cognitive decline, while in 
DLB cognitive symptoms debut simultaneously or before the symptoms 
of parkinsonism. Some studies suggest PDD and DLB are part of a 
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continuum and that it might be meaningful to separate them clinically 
but still recognize their common pathophysiological mechanisms in a 
research context [69, 102, 103]. 
There are no disease modifying treatments for DLB and PDD. 
Parkinsonism is treated with L-dopa just like in PD without dementia, 
and, like in AD, memory and attention deficits can be alleviated by 
AChE inhibitors like rivastigmine, galantamine and donezepil or NMDA 
receptor antagonists like memantine. Depressive symptoms can be 
managed by SSRI treatment, and hallucinations can be treated (very 
carefully and with low doses) with neuroleptics like quetiapine and 
clozapine. However, effective treatment of hallucinations in DLB and 
PDD is rare and adverse effects like worsened parkinsonism and 
increased risks of stroke and sudden cardiac death often outweigh the 
benefits [104].  
 
Creutzfeldt-Jakob disease (CJD) 
Sporadic CJD is a rare neurodegenerative disease that affects 
about 1/1 000 000 people per year worldwide, and is unlike the more 
common forms of dementias in that it is known to be transmittable 
[105]. CJD is caused by endogenous intracellularly misfolded proteins 
called prions, first discovered in the 1960s [106]. CJD is characterized by 
massive and escalating neuronal death, and the first symptom is usually 
rapidly progressive memory loss and dementia. Myoclonus, anxiety, 
depression and psychosis is also common but clinical presentations vary 
greatly [107]. While the sporadic forms of prion disease occur 
spontaneously, and are the most common forms accounting for about 
85% of all cases, there are also familial disorders caused by mutations in 
the PRNP gene encoding for the PrP protein, including familial CJD, 
fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome and 
Kuru [108-110]. A small part of prion disease cases are also caused by 
infection from external sources such as transplants contaminated by 
prions or by ingestion of meat infected with prions [111, 112]. All known 
prion disease start with the conformational change of the endogenous 
membrane protein PrPC into the disease associated PrPSc. By this change 
PrPSc acquires protease resistance and the ability to induce 
transformation of other PrPC proteins into PrPSc. PrPSc is prone to 
aggregation and form neurodegenerative amyloid fibrils [113]. All prion 
disease is fatal and no disease modifying treatments exist. There are also 
several prion diseases affecting other mammals all involving the same 
well preserved PRNP gene and PrP protein. Scrapie in sheep, bovine 
spongiform encephalopathy in bovines and chronic wasting syndrome in 
deer and moose all stem from the same transformation of host genome 
encoded PrPC into PrPSc [114, 115]. 
The physiological function of PrPC is not clear, and initial reports 
of PrPC knockout mice revealed no apparent phenotype abnormalities. 
However, more recent studies reveal adult-onset demyelination of the 
peripheral nervous system (PNS) in PrPC knockout mice, and further 
studies have corroborated a role for PrPC in myelin maintenance and 
cellular differentiation [116].  PrPC reportedly also acts as an inhibitor of 
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BACE1, thereby reducing the amount of Aβ produced with a potential 
protective effect against AD pathology [117].  
Protein misfolding occurs in a number of other diseases: AD, 
PD, Huntington’s disease, MND and more all feature aggregation of 
different endogenous proteins. Analogies and similarities between prion 
disease and other conditions involving protein aggregation have been 
found. For instance, evidence suggests that both tau and Aβ pathology in 
AD, as well as α–synuclein in PD might propagate through prion like 
mechanisms [118, 119]. This concept is discussed further in chapter 2.2.5 
and 2.2.6. 
   
Figure 3. PRPC, the normal and non-pathological strain of PRP. 
 Biomarkers of AD and neurodegeneration 
 
 
hile the clinical presentation in concert with cognitive, 
neurological and neuropsychological testing still forms 
the basis of the diagnostic process in dementia 
investigation, laboratory and radiological tests have been developed, and 
are increasingly used in clinical and research settings. In recent years, 
these tests have been included as recommended methods for supporting 
clinical evaluations in dementia diagnostics in several countries [62, 63]. 
 
The value of biomarkers 
The ability to readily identify and discern different causes of 
dementia as early as possible in the course of disease is essential in order 
to be able to provide optimal care and to enable administration of 
correct treatment. It is further important to identify means to be able to 
monitor disease progression and treatment effects. A host of drug trials 
aimed at treating AD have failed over the past few years. In fact, no new 
medications specifically aimed at treating AD have been approved by the 
FDA since 2003 (memantine being the latest). However, there is hope 
that this long dry spell may be nearing an end. In the most recent 
W 
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assessment there were 112 agents tested in 135 separate clinical trials 
underway, and in different stages of completion [38]. The principle focal 
points of drug development have sprung from the amyloid cascade 
hypothesis and aim at development and administration of antibodies 
targeting Aβ or related peptides to facilitate their removal, limit their 
production or hinder aggregation. An example of a highlight in this field 
is the antibody BAN2401, that binds to Aβ protofibrils and that has 
shown promising results in early phases or trial [120, 121]. A phase II 
clinical study on MCI patients who were administered BAN2401 was 
able to show not only dose-dependent reduction in amyloid plaques and 
slowed cognitive decline as measured by ADAS-Cog, but also increased 
CSF Aβ and reduced T-tau concentrations [122]. There is cause for 
optimism and keeping up hope that one of the many paths taken will one 
day lead to successful treatment of AD. 
Efficient biomarkers can provide aid in clinical trials by 
identifying suitable subjects for inclusion. It is likely that AD pathology 
must be targeted as early in the disease process as possible in order to 
prevent irreversible neuronal damage. It has been argued that the failure 
of some of the clinical trials in AD over the years can in part be 
attributed to treatment being administered to late in the course of the 
disease [36]. Signs of AD, including amyloid plaque build-up, have been 
shown to precede clinical symptoms by decades [34, 123, 124]. Using 
well characterized biomarkers can help find patients at an early enough 
stage of disease to be eligible for treatment, and help secure presence of 
AD pathology. Further, biomarkers can be used to monitor treatment 
effects in clinical studies. For instance, neurofilament light protein (NfL), 
the biomarker of interest in paper II of this thesis, can be considered a 
measure of rate of neurodegeneration in AD and other 
neurodegenerative diseases, and might be used to evaluate the efficacy of 
a given treatment or to compare dosages [125, 126].  
Another difficulty in treating dementia is the multifactorial nature 
of dementia disorders, and the difficulty in mapping out the disease 
processes present in the individual patient’s CNS [70]. Pure Alzheimer-
type pathology is rare, especially in the elderly [66]. There might also be 
as of yet unknown sub-classifications present in the spectrum of 
dementia disorders that have therapeutic significance. In the future, 
biomarkers might be used to obtain detailed information on the 
influence of different pathologies in the individual patient’s brains, and 
inform tailored treatment. 
There are several different modalities of biomarkers with a 
potential to allow for early and dependable diagnosis and prognosis as 
well as measures of rates of ongoing disease processes. 
 
Imaging biomarkers 
Structural magnetic resonance imaging (MRI) is the most widely 
used neuroimaging technique to investigate anatomical changes of 
neurodegeneration in vivo, and has contributed significantly to the 
understanding of different dementia disorders [127, 128].  In positron 
emission tomography (PET) and single photon emission CT (SPECT), 
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radioactive ligands are used to image structures, metabolism and 
perfusion of the brain, allowing for quantification of functional markers 
of neurodegeneration and specific neuropathological features of disease, 
such as amyloid plaques and neurofibrillary tangles in AD [128, 129]. 
PET and SPECT adds important information in the diagnostic process, 
and in the prognosis and management of dementia disorders in the 
clinical setting, and can reveal information on disease specific 
mechanisms of pathogenesis in the research setting [129]. The use of 
MRI in differential diagnosis is however limited due to lack of specificity 
for underlying pathology, as atrophy patterns might overlap across 
several dementia syndromes, and since the normal variability for 
structural measures is large [128]. Concordance between neuroimaging 
and CSF biomarkers of AD pathology is generally considered excellent 
[130-132].  
 
CSF biomarkers 
CSF - Function and characteristics 
The cerebrospinal fluid envelopes the brain and provides 
buoyancy and a buffer zone protecting the brain from physical trauma, 
while also removing metabolic waste by diffusing it out into the blood 
stream [133]. About 125-150 mL of CSF is in circulation at any given 
time, and the turnover rate is about 25 mL / hour [134]. Pathological 
processes in the brain leave traces in the CSF, which may thereby serve 
as a biochemical window into the brain and a valuable source of 
information for investigation of the biochemistry of the CNS. To use 
CSF biomarkers optimally a detailed understanding of their distribution 
and dynamics is required. Many different aspects might influence a 
biomarker’s concentration beside its relation to clinical pathology, such 
as age, sex, concomitant pathologies, genetic differences, rate of 
degradation of the analyte etc. AD is the most common and prominent 
dementia disorder and also the one where CSF biomarker research has 
been most fruitful. In this thesis we focus on exploring the large amount 
of data gathered in clinical routine, where assays for biomarkers in 
dementia have been available for several years. The biomarkers in our 
data include Aβ1-42, T-tau, P-tau, which all reflect different aspects of AD 
pathology, and NfL which is considered a more general biomarker of 
neuronal decay. 
Lumbar puncture 
CSF is sampled by means of a lumbar puncture (LP). An LP is 
performed by introducing a needle into the subarachnoid space of the 
lumbar spinal column below the termination of the spinal cord, usually 
between vertebrae L3/L4 or L4/L5 [134]. For dementia biomarker 
analysis a volume of about 12 mL of CSF is normally collected and put 
in polypropylene tubes before further processing. Lumbar puncture is a 
safe procedure with little side effects, the most commonly reported being 
post-LP headache, a benign condition that typically resolve within a week 
and that occur in about 10% of patients when atraumatic needles are 
used [134].  
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Biomarkers of AD pathology 
There are several established CSF biomarkers of AD correlating 
to different characteristics of AD pathology. A classical, but somewhat 
disputed, interpretation of the three major AD biomarkers are that low 
levels of Aβ1-42 correlate with senile plaque load, levels of T-tau increase 
with higher rates of neuronal death, and levels of P-tau correlate with 
neurofibrillary tangle pathology [135]. Various composite biomarkers has 
also been suggested and evaluated. For example, the P-tau/Aβ1-42 ratio 
has been shown to have particularly good discriminatory power in AD 
towards other dementias, presumably because it integrates information 
about amyloid and tau pathology, the core hallmarks of AD [136-138]. 
Another prominent composite biomarker is the Aβ1-42/Aβ1-40 ratio, where 
the dynamic of low Aβ1-42 concentrations in contrast to unchanged 
concentrations of the Aβ1-40 in AD is employed [139]. This ratio is 
probably superior since it adjusts for the between-person variability in 
overall amyloid peptide metabolism. In patients with a clinical AD like 
presentation (also in pre-dementia stages) a pattern of low levels of Aβ1-42 
in combination with elevated levels of T-tau and P-tau should strengthen 
the suspicion on AD. However, as previously discussed, other common 
dementia disorders might overlap both in clinical symptoms and CSF 
characteristics, and mixed pathologies are common [140-144]. 
  
Aβ1-42 
We use the term Aβ to refer to 
peptides that are derived from the 
amyloid precursor protein (APP). APP 
is a membrane bound protein that can 
be cleaved by three enzymes, α-, β-, and 
γ-secretase. Cleavage by γ- and β-
secretase (BACE1) sheds several Aβ-
isoforms, including Aβ1-40 and Aβ1-42, 40 and 42 amino acids long 
respectively. Aβ1-42 is produced by BACE1 and γ-secretase cleavage and 
prone to aggregation, while residues produced by α-secretase cleavage are 
not (figure 4). Aβ1-40 is also produced by BACE1 and γ-secretase cleavage 
but does not contribute to aggregation at the same rate as Aβ1-42. High 
concentrations of intracerebral 
Aβ1-42 or increased Aβ1-42/Aβ1-40 
ratios lead to amyloid plaque 
build-up. In sporadic AD, 
production of Aβ is thought to be 
shifted into higher rates of Aβ1-42, 
or alternatively the clearance of 
Aβ is reduced [145]. The 
physiological roles of APP and Aβ 
are also not clearly mapped out. 
APP knock-out mice exhibit 
growth and brain weight deficits, 
reduced grip strength, agenesis of Figure 4. APP processing by α-, β- and γ-secretase. 
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the corpus callosum and several other abnormal traits [146]. Mutations in 
APP at the BACE1 cleavage site in humans increase Aβ1-42 production 
and are associated with ADAD [147]. BACE1 knock out mice don’t 
produce Aβ1-42 and are healthy and fertile but exhibit memory and 
behavioral deficits [148]. Presenilin is the sub-component of γ-secretase 
that is responsible for APP cleavage. Mutations in the presenilin genes 
PSEN1 and PSEN2 are the most common causes of familiar early onset 
AD in humans [149]. Most mutations in presenilin do not increase the 
amounts of Aβ produced but shunts production into more Aβ1-42 at the 
cost of less Aβ1-40 [150, 151]. 
AD pathology leads to lower concentrations of Aβ1-42 in CSF as 
compared to healthy controls [135]. The most commonly accepted 
explanation for this is that intracerebral Aβ1-42 aggregation prohibits 
Aβ1-42 clearance into CSF. This has been corroborated by autopsy studies 
finding correlations between low Aβ1-42 in ventricular CSF and high 
numbers of amyloid plaques in the neocortex and hippocampus [152]. 
Cerebral Aβ aggregation is an early event in AD and might precede 
clinical symptoms by decades. 
Amyloid positivity in subjects with 
normal cognition has been shown 
to be associated with observable 
clinical symptoms 10-15 years 
before they emerge [153]. After it 
was concluded that the main 
component of amyloid plaques in 
AD was Aβ, and that Aβ was a Figure 5. Aggregated Aβ1-42 in AD 
soluble peptide secreted by a variety of cell types, the search for means 
of measuring Aβ in CSF begun [154]. The first ELISAs developed 
measured total Aβ levels and failed to discriminate different Aβ isoforms, 
and thus also AD patients from healthy controls [155]. It was later found 
that several different forms of Aβ existed and that Aβ1-42 was the 
predominating form deposited in amyloid plaques [156, 157]. In light of 
these discoveries immunoassays targeting Aβ1-42 were developed and 
shown to identify lower concentrations of CSF Aβ1-42 in AD patients as 
compared to healthy controls [155, 158, 159]. A commercial sandwich 
ELISA assay (INNOTEST® β-amyloid1-42) was used for CSF Aβ1-42 
measurements in paper I of this thesis. 
Amyloid plaques are not exclusive to AD. For instance, in DLB, 
amyloid plaque formation is an early feature, and PD patients who 
develop PDD also show heightened amyloid burden [160, 161]. These 
overlaps might indicate presence of Aβ in non-AD pathology, but might 
also indicate comorbidities. 
It has long been assumed that the insoluble amyloid plaques in 
AD are the instigating factor in AD pathogenesis [21].  However, this 
has been disputed by a growing body of evidence supporting the 
importance of the prefibrillar stage of amyloid plaques, soluble Aβ 
oligomers, in inducing synapse loss and neurotoxicity in AD [162]. 
Studies have shown Aβ oligomers to be more cytotoxic than fibrillary Aβ 
plaques in general and to inhibit long-term potentiation of synapses both 
in vivo and in in vitro [163, 164]. The so called Arctic mutation in the APP 
gene causes a form of ADAD, and was discovered in a Swedish family in 
the early 2000s [165]. However, the Arctic mutation cause increased 
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formation of large soluble Aβ oligomers and protofibrils, and the brains 
of diseased patients with the mutation don’t exhibit amyloid plaques in 
the classical sense. Interestingly, NFTs occur at the same rate as in 
sporadic AD, further supporting the idea of Aβ oligomers being 
important in AD pathology [166]. 
As previously mentioned, evidence has been put forth to support 
a prion like propagation of Aβ pathology. Several research groups have 
injected brain tissue from deceased AD patients into the brains of 
transgenic human APP mice and could then observe Aβ plaques develop 
and propagate from the injection site throughout the rodents’ brains 
[119, 167]. The degree of Aβ seeding in the mouse brain has been found 
to be in direct proportion to the concentration of the injected brain 
extract [168]. Evidence promotes a propagation of Aβ pathology through 
axonally connected brain areas, unlike PrPSc that spread to anatomically 
adjacent brain areas via the brain interstitial fluid [169, 170]. 
  
Tau 
Tau proteins are most 
abundant in neurons, but are also 
expressed in other cells in humans. 
Under normal conditions their main 
function is to stabilize microtubules 
and primarily do so in non-myelinated 
axons [155]. There are six isoforms of tau encoded by the same gene 
(MAPT) but results of alternative splicing. The tau isoforms are 
distinguished by their number of binding domains and their resulting 
performance in microtubule stabilization. Tau is a phosphoprotein with 
more than 30 potential phosphorylation sites and the tubule binding 
power of tau is regulated by a host of kinases [68]. Phosphorylated tau 
disrupts microtubule organization and leads to increased neurofibrillary 
plasticity or degeneration [171, 172]. Hyperphosphorylated tau of all 
isoforms have severely reduced affinity for microtubules and is prone to 
aggregation leading to formation of intracellular NFTs, thereby rendering 
a normally soluble protein resistant to degradation and clearance [173]. 
NFTs are neurotoxic and mediate neuronal death and cognitive decline 
in AD. Tau inclusions are not specific to AD, but key components of the 
pathology in a group of diseases called tauopathies, i.e. 
neurodegenerative diseases associated with neurofibrillary or glial 
fibrillary tangles. However, tau aggregates differ across tauopathies in 
their composition and locale. Astrocytic tufts form in PSP, astrocytic 
plaques in CBD and Pick bodies in FTD [174]. 
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The precise role of tau in AD and neurodegeneration is unclear 
and has been debated. Evidence suggests that tau is needed for Aβ 
neurotoxicity in AD, as neurons from tau knockout mice, unlike those 
from normal mice, are resistant to exposure to Aβ [175]. Tau dysfunction 
might cause neuronal damage in two different ways, by loss of function 
and by gain of cytotoxicity. Data indicates that increased levels of 
intracellular Aβ cause tau to hyperphosphorylate and detach from 
microtubules, impairing axonal transport and leading to synaptic 
dysfunction. Tau is then deposited in the neuron’s somatodendritic 
departments [176]. Hyperphosphorylated tau has a tendency to self-
aggregate into filaments that ultimately form NFTs, a classical 
neuropathological hallmark sign of AD pathology, and long considered 
neurotoxic. However, it could also be that the NFTs are the end-product 
of a process where an intermediary product is the neurotoxic agent, i.e. 
the NFTs themselves don’t propagate neurotoxicity. Some studies 
indicate that soluble, hyperphosphorylated tau is closer related to synapse 
loss and neuronal decay than NFTs by showing that these destructive 
events occur in cell models in the presence of mutated tau independent 
of NFT formation, indicating that NFTs are merely a side effect of 
neurodegeneration [177, 178]. 
 
 
Figure 6. Tau aggregations in a NFT in AD (left) and a narrow Pick filament in FTD (right). 
 
The T-tau concentration in CSF has historically been considered 
a biomarker of neurodegeneration. However, recent evidence suggests 
that the increase in CSF tau concentrations arise due to ramped up 
phosphorylation, and is released as a response to Aβ exposure [179]. In 
any case, T-tau is increased in AD and can effectively discriminate AD 
patients from healthy controls [180]. In some other tauopathies, 
including FTD, CBD, and PSP, CSF T-tau concentrations are 
surprisingly not distinguishable from healthy controls [181]. In most 
non-AD dementias, such as DLB, PDD and VaD, T-tau concentrations 
are also normal or close to normal [182]. However, T-tau concentrations 
are not exclusively increased in AD. The most dramatic increase in CSF 
T-tau concentrations can be seen in CJD, where nearly exponential 
increases can be seen as the neurodegeneration spread through-out the 
affected brain, as studied in paper III of this thesis [183]. In stroke and 
traumatic brain injury (TBI), CSF T-tau concentrations also increase 
[184]. In conclusion T-tau is a biomarker reflecting the intensity of 
neurodegeneration in several disorders, and is considered one of the 
hallmark biomarkers of AD, where elevated concentrations in CSF might 
be a response to Aβ exposure. 
Tau is encoded by a single gene, MAPT. No known MAPT 
mutations are known in AD, but rare familial cases of non-AD 
tauopathies have been linked to MAPT mutations. About 100 families 
with MAPT mutations have been reported. Mutated tau has reduced 
ability to bind to microtubules and lead to tauopathies like PSP, CBD, 
Pick’s disease (a form of FTD) and the rare autosomal dominant disease 
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frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17)  [184]. 
As with Aβ accumulation, evidence have been put forth to 
support a prion-like propagation of tau aggregation. Defining features of 
prion-like behavior include a protein or protein aggregate gaining 
insolubility and protease resistance, neurotoxicity and the ability to 
propagate these traits to proteins in adjacent cells, inducing a wild fire 
like spread [185]. Mounting evidence suggest that tau might fulfill these 
criteria. As previously described tau aggregates are neurotoxic and 
insoluble. Studies have also shown uptake of tau by cells through specific 
mechanisms, notably by interaction with heparin sulfate proteoglycans 
that also interact with pleiotrophin, the subject of interest in paper IV of 
this thesis [186, 187]. In addition, studies have shown that tau pathology 
in AD do not distribute randomly but spread following neuronal 
networks throughout the brain, possibly implying connectivity as a key 
for propagation [188, 189]. Several studies have further shown seeding, 
i.e., the induction of aggregation of soluble tau by abnormal tau [190-
192]. Introduction of synthetic tau fibrils into the brains of mice induce 
build-up of NFT-like inclusions that propagate from the injection site 
into connected brain regions [118]. 
 
  
NfL 
Another CSF biomarker 
of importance in dementia and 
neurodegeneration in general is 
NfL, which is part of a family of 
proteins, neurofilaments, 
consisting of three members: 
neurofilament light, medium and 
heavy. NfL is predominantly expressed in large-caliber myelinated axons 
where it serves as a scaffolding protein, providing structural integrity to 
the axon. White matter lesions and other injuries to subcortical brain 
regions induce NfL release into CSF, and conditions that exhibit 
increased CSF NfL concentrations include dementias such as FTD, 
VaD, HIV-associated dementia and AD but also multiple sclerosis, 
stroke, traumatic brain injury (TBI) and neuroinfectious conditions [193-
197]. NfL has been less studied than Aβ1-42, T-tau and P-tau but has great 
potential for use in disease monitoring and prognosis in 
neurodegenerative conditions through its cross-disease biomarker 
properties, correlation to on-going neurodegeneration, and accessibility 
in being able to measure in serum and plasma as discussed below. 
 
Emerging biomarkers and the pursuit of prospects 
The amyloid cascade hypothesis, although not yet proven, might 
be considered the core model of the disease processes in AD, and the 
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biomarker triad of Aβ1-42, T-tau and P-tau each reflect the main 
components of this model. However, recent studies in AD biomarkers 
highlight several other important pathological changes and the molecules 
that reflect them.  
Neurogranin (Ng) is a protein involved in long term 
potentiation/depression of synapses, and can be used as a biomarker of 
synaptic loss and to predict rate of cognitive decline in AD [198, 199]. 
Portelius et al. has further shown that Ng can contribute to the 
diagnostic accuracy of the core AD biomarkers (Aβ1-42, T-tau and P-tau) 
and increase the discrimination of AD and other neurodegenerative 
disorders [200].  
The physiological role of YKL-40 is unclear, but it is known as a 
marker of activated astrocytes and microglia, and to be upregulated in 
several conditions and disorders characterized by inflammation 
including, but not limited to, inflammatory bowel disease, rheumatoid 
arthritis, scleroderma, certain infections and cancers like melanoma and 
myeloid leukemia. It has also been suggested as a biomarker for 
neurodegeneration in traumatic brain injury, multiple sclerosis and AD 
[201-203]. Data suggest that YKL-40 levels are elevated in AD but also 
in FTD and prion disease but not vascular dementia and PD [204]. 
The platelet-derived growth factor receptor-β (sPDGFRβ) is 
abundant in brain capillary pericytes and envelops capillary blood vessels 
in the brain [205]. When measured in CSF, sPDGFRβ is closely 
correlated with blood-brain-barrier dysfunction and was recently shown 
to be increased in individuals with incipient cognitive dysfunction in AD 
independent of other CSF biomarkers [206].  
In short, additional biomarkers can help provide a deeper 
understanding of the pathological mechanisms involved in AD, more 
nuanced and dynamic characterizations of processes contributing to 
neurodegeneration and might help tailor treatments for individual 
patients in the future. 
Pleiotrophin 
In paper IV, the 
discovery of a new potential 
biomarker of AD is laid out. 
Using a novel strategy for 
hypothesis generation through 
analysis of mass spectrometry 
data applied in a large sample of patients (n = 120), a peptide from the 
protein pleiotrophin, PTN151-166, was discovered as a new candidate 
biomarker of AD. Pleiotrophin is expressed in the CNS and PNS 
specifically during embryonic development, but also in non-neural 
tissues, including lung, kidney, gut and bone [207]. While previously not 
implicated in AD, pleiotrophin is abundantly expressed in the adult 
hippocampus and can be induced by ischemic insults or neuronal 
damage in the entorhinal cortex, areas of high interest in AD since tau 
pathology typically develops there early in the disease process [208-210].  
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PTN mainly exerts function by binding to the receptors heparan 
sulfate proteoglycan N-syndecan and chondroitin sulfate proteoglycan 
receptor-type protein tyrosine phosphatase ζ (PTPRZ), and evidence 
suggest that the C-terminal region of the protein, the peptide identified 
as a possible AD biomarker in paper IV, is vital to maintaining stable 
interactions with these receptors [211-214]. As previously mentioned, 
evidence has indicated that tau pathology might propagate in a prion-like 
fashion and more specifically by interactions with heparan sulfate 
proteoglycans [186, 187]. Binding of PTN to PTPRZ is thought to 
promote clustering and by that inhibiting its function [215]. A possible 
hypothesis for the role of PTN151-166 in AD could thus be that PTN 
binding to heparan sulfate proteoglycans such as PTPRZ is hampered by 
some unknown post translational processing of PTN where its active C-
terminal region, i.e. PTN151-166, is shed, increasing the concentration of 
PTN151-166 in CSF and facilitating axonal tau pathology spread through a 
disrupted inhibition of PTPRZ.  
Another known receptor of PTN, LDL receptor-related protein 
(LRP), is also a major receptor of APP and apoE, and has been 
genetically linked to AD [216, 217]. Evidence suggest PTN and midkine, 
another highly homologous protein, both bind and activate LRP, 
possibly by formation of a receptor complex [218].  LRP has several 
different functions and many of them are important in relation to AD 
pathology. Neurons need cholesterol to function and import cholesterol 
by apoE via LRP receptors. It has been proposed that decreased LRP 
leads to intracellular cholesterol deficiency, and studies have shown 
increased Aβ production correlate with cholesterol reduction [219]. LRP 
expression is reduced as a part of normal aging, providing a possible link 
to age related increase in Aβ build-up [220]. Further, LRP is involved in 
increasing Aβ production via processing of APP, but also clearance of 
Aβ by endocytosis of complexes formed by Aβ, apoE and lactoferrin 
[221]. LRP, as well as PTN, can be found deposited in amyloid plaques 
in AD brains [222-224].  
Further studies are needed to detail the true meaning of the 
PTN151-166 finding in paper IV, but the study stands on its own as a 
tantalizing hint at the potential fruitfulness of further hypothesis 
generating studies. 
Plasma and blood biomarkers 
Blood is a more accessible source of biomarker information than 
CSF. Medical care professionals in some countries oppose the 
invasiveness and time consuming nature of the lumbar puncture and 
might be more willing to perform the less intrusive and simple procedure 
of taking a blood sample, which would accelerate the implementation of 
biomarkers in clinical practice. Blood biomarkers might serve an 
important role as a screening tool at primary care units, mainly to exclude 
patients with memory complaints but no signs of biochemical AD 
pathology from referral. A blood biomarker with high sensitivity would 
be ideal for this purpose, even with low or modest specificity. Patients 
that test positive would be referred to a memory clinic for further and 
more costly investigations, including CSF, PET, MRI and neurocognitive 
examination.  
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Blood is in less close proximity to the CNS by virtue of the 
blood-brain-barrier, to different degrees hindering potential biomarkers 
from diffusing into the blood stream. New technological advances in 
recent years have yielded ultrasensitive measurement techniques able to 
detect the by orders of magnitude lower concentrations of brain-specific 
proteins in blood [225]. Plasma concentrations of NfL have been shown 
to correlate well with CSF concentrations and predict cognitive decline, 
and might be particularly suitable as a measure of longitudinal disease 
progression in clinical trials, but also as a tool in AD diagnostics where a 
receiver operating characteristics (ROC) area under the curve (AUC) of 
0.87 against healthy controls have been measured in the ADNI cohort 
[226-230]. A study of blood NfL in ADAD showed increased NfL levels 
before symptom onset and a correlation of NfL levels and time to 
symptom onset [126].  
Plasma tau correlates with higher CSF tau and lower CSF Aβ1-42, 
and has shown strong associations with AD in meta-analysis with 
average tau levels 1.95 times increased vs healthy controls [180]. A study 
of plasma tau in the ADNI cohort confirmed this result but showed a 
significant overlap between normal aging and AD [231]. Yet another 
study of plasma tau found a correlation of tau and cognitive decline 
independent of CSF Aβ, suggesting a non-disease specific 
neurodegeneration measuring property of plasma tau [232].  
ELISA studies of plasma Aβ1-42 and Aβ1-40 have shown both 
biomarkers to be unaltered in AD compared to healthy controls, while a 
single-molecule array (Simoa) study have shown both markers to be 
decreased in AD, as opposed to in CSF where Aβ1-42 concentrations are 
low, but Aβ1-40 normal [233]. However, while study results have been 
conflicting, recent studies have shown that very high performance in 
predicting brain amyloid-β burden can be achieved using plasma 
Aβ1-42/Aβ1-40 ratios measured using mass spectrometry [234]. 
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Aims 
 
 
he general aim of this PhD project was to study and expand 
the understanding of the properties of known CSF biomarkers 
of AD and neurodegeneration across a wide array of 
neurodegenerative diseases, including the most prevalent dementia 
disorders. 
 The specific aim of study I was to study the prevalence of AD-
like pathology in dementias besides AD, and the dynamics of the CSF 
biomarkers Aβ1-42, T-tau and P-tau in relation to clinical outcomes of 
disease severity across dementia disorders. We hypothesized that the 
most clear AD-like biomarker pattern would be found in AD, but that 
biomarker levels in other dementias also carry similarities to AD.  
 The specific aim of study II was to study the potential of CSF 
NfL as a biomarker of on-going axonal degeneration, and its association 
with clinical outcomes of survival and cognitive measures in the major 
dementia disorders. We hypothesized that CSF NfL concentrations 
T 
would be particularly high in diseases characterized by white matter loss 
and that CSF NfL concentrations would predict survival. 
 The specific aim of study III was to evaluate the performance of 
T-tau and the T-tau/P-tau ratio in diagnosis of CJD. We further aimed 
to study the longitudinal dynamics of the CSF T-tau concentrations in 
CJD and relations to survival. We hypothesized that CSF T-tau levels 
would distinguish CJD from important differential diagnoses, and that 
CSF T-tau would predict survival. 
 The specific aim of study IV was to develop and test the 
feasibility of a new strategy of analyzing LC MS/MS data to generate 
hypotheses for new biomarkers in AD. We hypothesized that the new 
strategy of data analysis would be fertile grounds for biomarker 
discovery. 
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Methods 
 
 
he first three studies included in this thesis compile data from 
clinical routine measurements of CSF biomarkers. These 
measurements were obtained by enzyme-linked 
immunosorbent assays (ELISAs) in clinical routine at the neurochemistry 
laboratory at the Mölndal site of the Sahlgrenska university hospital, 
which serves the whole of Sweden in CSF biomarker measurements. 
Paper IV explores the peptidome in AD in relation to MCI and healthy 
controls using mass spectrometry. The following chapter will provide a 
background to ELISA and mass spectrometry as the main techniques for 
biomarker measurements used in the production of the studies of this 
thesis. 
ELISA 
ELISA is a common technique used in both clinical and research 
settings for analyzing ligands, most commonly proteins, in liquids. It was 
developed in the 1970s and uses antibodies directed at the ligand to be 
T 
measured [235]. There are several types of ELISA tests where analytes 
and antibodies are used in different ways. In sandwich ELISA, which 
was used for all samples in the studies in this thesis, samples are 
introduced to a surface, usually the bottom of a well out of an array of 
wells on a plate, pre-coated with capture antibodies (figure 7). A second 
antibody directed at the ligand and conjugated with an enzyme, typically 
horseradish peroxidase, is added. The final step is to add a substance 
containing the enzyme’s substrate. When horseradish peroxidase is used, 
this leads to a detectable and quantifiable change in color where enzyme-
carrying antibodies are bound to ligands in turn bound to the antibody-
coated surface. Other enzyme/substrate combinations may be used that 
employ other mechanisms for quantification such as spectrophotometry, 
where transmission of specific wavelengths of light is measured [236]. 
 
Figure 7. The principle of sandwich ELISA. The targeted protein binds to antibodies attached to 
the well. Enzyme labeled antibodies are then added, and bind to the targeted protein. The enzyme 
substrate is subsequently added and the amount of color change is recorded.   
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Mass spectrometry 
Mass spectrometry (MS) is a technique to measure molecular 
mass that has found extensive use in biology and biomedicine for 
analysis of a broad range of biomolecules. In MS, the analyte molecules 
are transferred to the gas phase and ionized, after which electric and/or 
magnetic fields are used to separate them according to their mass-to-
charge ratio (m/z). The first steps on the road leading up to modern 
mass spectrometry trace all the way back to the late 19th century, and 
several key advances in the development of the techniques have yielded 
Nobel prizes to their inventors [237-239]. Today, MS is used widely in 
many different fields to study physical, chemical or biological properties 
of molecules. It is used by governments and regulatory services to secure 
the cleanliness of air, the purity of water, quality of food and absence of 
contamination in medical agents [240]. Athletic oversight committees use 
MS in their monitoring of illegal substance use in athletes [28]. 
Miniaturized mass spectrometers have even been sent to Mars, Venus, 
Jupiter and Saturn on board the Viking, Pioneer, Galileo and Cassini 
landers for the purpose of analyzing planetary atmospheres and soil [241, 
242].  
The spectrometry process is divided into three key stages: 
Ionization, analysis and detection. These three stages can individually be 
accomplished in many different ways, and many different instrument 
designs exist to suit the analytical task and the properties of the analyte 
molecules. MS was long inapplicable to the analysis of polypeptides; the 
energy required to transfer these high-mass molecules to the gas phase 
and ionize them led to their decomposition, prohibiting their mass 
analysis. That was changed by two major scientific breakthroughs in the 
field in the 1980s. The 
first was the discovery 
of matrix-assisted laser 
desorption/ionization 
(MALDI), an ionization 
technique where the 
crystallized analyte is 
mixed together with a 
matrix of relatively light-weight organic compound that strongly absorbs 
UV or IR light. The crystals are then irradiated by a pulsed laser (figure 
8). The matrix molecules absorb the major part of the energy, leading to 
desorption of a portion of the sample, bringing along the analyte 
molecules to the gas phase while simultaneously protecting them from 
decomposition. The produced analyte ions are then transferred into the 
mass analyzer and subsequently to the detector [243, 244]. 
The second breakthrough in biological MS was the invention of 
the electrospray injection (ESI), which was first described in the 
literature in by Yamashita and Fenn in 1984 [245]. Fenn was awarded the 
Nobel prize in 2002 for his contributions [237]. In ESI the liquid 
containing the analyte in aqueous/organic solvent is ejected through a 
thin needle positioned in front of the MS inlet. High voltage (2000-4000 
V) applied between the needle and the MS inlet causes the electrospray 
process to occur, resulting in an aerosol of charged droplets being 
infused into the mass spectrometer. The solvent evaporates due to heat 
Figure 8. MALDI principle, courtesy of Carson Szot, Antony 
Croxatto, Guy Prod’hom, Gilbert Greub under CC BY-SA 4.0 
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being applied, sometimes assisted by a nitrogen gas flow, leaving the 
analyte bare, carrying the charges each containing droplet confined. 
Using MALDI or ESI large molecules, like proteins and peptides, could 
now be studied. In this thesis, hybrid quadrupole Orbitrap mass 
spectrometers (Q-Exactive and Tribrid Fusion from Thermo Scientific) 
were used for ESI-MS in the fourth paper. 
 
Orbitrap 
 The Orbitrap mass 
analyzer was introduced in the 
early 21st century by Makarov et 
al. [246]. It provides unparalleled 
performance in resolution, mass 
accuracy, through-put and 
dynamic range  and have set the 
standard for high-resolution 
mass spectrometers in 
proteomics [247]. The Orbitrap 
exploits the oscillational behavior of ions around a central electrode in an 
electrostatic field to obtain precise m/z values (figure 9). The behavior is 
reminiscent of planetary bodies getting trapped in gravitational wells. 
Ions injected into the Orbitrap oscillate coherently along the central 
electrode with a frequency that is proportional to the m/z of the ion. The 
oscillating ions induce an image current that is picked up by the outer 
Figure 9. Schematic representation of an Orbitrap 
mass analyzer. Reprinted with permission from 
Thermo Scientific, copyright 2019. 
electrodes. The detected wave signal is transformed using Fourier 
transformation from the time domain into the frequency domain, and 
after calibration into m/z scale. This analyzer affords very high, i.e. sub-
ppm, mass accuracy [248]. 
 
Tandem mass spectrometry 
Another key concept in proteomic MS is tandem mass 
spectrometry, also known as MS/MS or MS2. While the general principle 
for MS is to measure the mass-to-charge ratio (m/z) of intact ions, 
tandem mass spectrometry involves a second isolation step of a selected 
ion and subsequent fragmentation of this ion. The m/z of the produced 
fragments is then measured, providing means for obtaining structural 
information on the analytes. The atomic bonds between amino acids in 
proteins and peptides vary in stability depending on the properties of the 
bound amino acids and the nearby chemical environment, resulting in 
partially predictable fragmentation characteristics [249]. Thus, the 
information obtained in a tandem mass spectrum can be used in several 
different ways. Databases exist, such as Mascot (Matrix Science) or 
SeQuest (Thermo), that facilitate the commonly used method of 
precursor ion fingerprinting. These databases list known precursor ion 
fingerprints, i.e. molecular weights and fragment patterns with 
corresponding source protein identity information. Detected m/z and 
fragment patterns are run against these databases to find their identities. 
Although efficient and well established, these databases cannot deliver 
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full coverage and identify all fragment spectra. However, peptides that 
are not recognized in database searches can still be identified. By 
exploiting the predictability of how amino acid sequences fragment in 
combination with the known molecular weights of the 20 amino acids 
coded for in the human genome, and possible fragment peptide weights 
calculated in silico, the peptide sequence of the fragmented peptide can be 
calculated. This process is called de-novo-sequencing and can be aided 
by software such as Peaks (Bioinformatics solutions Inc.). In short, de-
novo-sequencing is carried out by measuring the distance (in m/z) 
between peaks in the MS2 spectra, and matching the distances against 
amino acid weights, step by step constructing so called sequence tags and 
gradually working against revealing the identity of the peptide being 
sequenced [250]. 
 
Labeling techniques 
MS spectra can only be used to reach relative quantifications of 
abundances of peptides in a sample. This prohibits evaluation of most 
biomarkers as they typically need to be assessed in relation to reference 
ranges and cut-offs, most commonly derived from examinations on 
patients vs healthy controls. Stable isotope labelling can be used to 
nominally quantify the concentration of a specific compound in a 
solution. A peptide of interest is selected and artificially synthesized with 
the addition of a heavy isotope label. A known quantity of the heavy 
isotope peptide is then added to the sample before MS2 analysis. The 
ratio of the surface area under the heavy and the light (or endogenous) 
isotope peak can then be used to quantify the concentration of the light 
compound in the sample. 
In isobaric labeling by tandem mass tags (TMT), chemical labels 
designed to be identical in structure and molecular weight but vary in the 
distribution of heavy isotopes are introduced [251]. The labels react with 
primary amines in the samples to be analyzed, which can then be pooled 
together and analyzed in one run. When exposed to fragmentation 
energies the labels shed reporter ions that are unique in m/z, revealing 
the relative abundances of labeled peptides in the pooled samples. The 
isobaric labelling serves two purposes: it enables multiplexing, i.e. 
running analysis of several samples in one LC-MS run, and it improves 
the accuracy and robustness of quantitative MS by introducing a 
reference substance to relate intensities of measured ions to. In 10-plex 
TMT labeling, that was used in paper IV of this thesis, 10 samples are 
pre-prepared individually with one of the 10 TMT reagents, and 
subsequently pooled together before the LC-MS run.  
 
Shotgun proteomics 
Protocols for preparing protein samples for MS analysis vary 
widely depending on experimental goals and analytical methods to be 
applied. In hypothesis free experimentation, where the aim is to explore 
and map out a proteome as exhaustively as possible, shotgun proteomics 
is a common strategy. In shotgun proteomics proteins and peptides in 
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complex samples are first digested using a protease, most commonly 
trypsin, and the resulting peptides are then separated by liquid 
chromatography [252, 253]. By trypsination large proteins are truncated 
into smaller molecules that are easier to separate, ionize and fragment 
successfully. This approach allows for a wide scope of analysis, high 
through-put and good sensitivity.  
 
Registries 
Svedem – The Swedish dementia registry 
Svedem is a national registry that was started 2007. It collects 
data on patients with dementia diagnoses in Sweden by collecting reports 
filled out be the physicians following the patients. All memory clinics and 
77% of all primary care units in Sweden are connected to the Svedem 
network. Information on diagnosis, date of diagnosis, clinical 
characteristics of each patient, cognitive assessments and prescribed 
medications are recorded. [254] 
 
The Swedish mortality registry 
The Swedish mortality registry is a national registry managed by 
the Swedish national board of health and welfare. It provides data for the 
official statistical reports on rates and causes of death of Swedish 
citizens. It was started in 1961 and is updated yearly [255]. All deceased 
citizens are registered with personal information and information on 
date, time, place and cause of death coded according to ICD. A total of 
60 variables are recorded for each death. 
Statistics 
 Where distributions of quantitative measures were significantly 
skewed, non-parametric methods or log-transformed data was used 
throughout the papers in this thesis. Group differences of averages, 
medians and categorical parameters were analyzed by ANCOVA, median 
regression, chi-square analysis, Mann-Whitney U and Kruskal-Wallis 
analysis. Linear and multiple regression models were fitted for 
association testing between continuous variables, and log-
transformations were applied where appropriate. Association testing was 
also carried out using Spearman rank correlations and t-tests.  
ROC analysis was used to evaluate biomarker profiles and 
diagnostic performance, including sensitivity, specificity and predictive 
values. Survival analysis was conducted using Cox regression. 
 In paper I clustering of data was performed using the SPSS 
TwoStep algorithm, a variant of K-means clustering, where a preceding 
step determines to optimal number (k) of clusters to put into a K-means 
clustering run. 
 Statistical analysis was carried out in SPSS (IBM, Armonk, New 
York) and Stata (StataCorp, College Station, TX). 
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Ethics 
Clinical data on patients gathered from Svedem was used in 
paper I-III of this thesis. All patients in Svedem were informed about 
their participation in the registry, the potential use of their submitted data 
for research, and had the right to decline participation. Biomarker data 
was fetched from the clinical routine lab database at the Sahlgrenska 
university hospital, Sweden. Paper I-III of this thesis was approved by 
the regional ethical committee at the University of Gothenburg (dnr: 
752-12). 
In paper IV, CSF and clinical data from 120 patients from the 
Amsterdam Dementia Cohort was used for biomarker discovery. All 
subjects gave written consent for usage of their samples and clinical data 
for research purposes, and the study was approved by the local Medical 
Ethics Committee at VU University Medical Center, Amsterdam. 
Biomarker validation was performed in CSF samples assembled from the 
BioFINDER study at Skåne University hospital, Sweden. The study was 
approved by the Regional Ethics Committee in Lund, Sweden, and the 
patients and/or their relatives gave their informed consent for research. 
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Results  
 
 
Paper I – The core CSF AD biomarkers in the 
dementia spectrum 
 
 
aper I explores the core CSF biomarkers of AD, T-tau, P-tau 
and Aβ1-42 in all of the most prevalent dementia diagnoses. 
While the biomarkers in this study reflect different 
neuropathological aspects of AD, there is known to be a large overlap of 
these pathologies as well as clinical phenotypes in other dementias. By 
cross-referencing the lab database at the Sahlgrenska university hospital 
with Svedem, an in this context unparalleled amount of study subjects 
could be garnered (n = 5676).  
We found, as expected, the most clear AD-like biomarker pattern 
in patients with clinically diagnosed AD. However, large shares of 
P
patients with other clinical dementia diagnoses also exhibited a 
biomarker pattern indicating possible concomitant AD pathology. 
Pathologic Aβ1-42 concentrations were detected in more than 50% of 
VaD, DLB and PDD patients. This is consistent with previous findings, 
including post-mortem neuropathological examinations, and further 
demonstrates evidence of the widespread prevalence of AD-like disease 
processes in other dementia disorders [256, 257]. Evidence of tau-
pathology was less widespread than that of Aβ-pathology but still 45% of 
VaD, 44% of FTD, 32% of DLB and 29% of PDD patients had 
pathological levels of either T-tau or P-tau. This could indicate tau-
pathology, but could also be attributed to tau-leakage due to general 
neurodegeneration or normal variability in CSF tau concentrations. 
 Using cluster analysis, we were able to identify a natural 
classification of patients with regards to their AD biomarker CSF 
concentrations. Nearly half of the patients sorted into a cluster 
characterized by pathological AD biomarkers, indicating ongoing AD 
pathology. This cluster was dominated by the clinically diagnosed AD 
groups, while the other cluster contained a majority of the other 
dementias, corroborating the connection between the hallmark AD 
biomarker profile and the clinical phenotype of AD. 
The large number of study subjects in this study provided 
enough power to detect small variations in cognitive performance in 
relation to biomarker concentrations, an aspect previously relatively 
unexplored. In late onset AD (LAD), but not in the other diagnoses, 
negative trends of lower MMSE scores were correlated to higher CSF 
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concentrations of both T-tau and P-tau, and also lower concentrations of 
CSF Aβ1-42.  
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Paper II – CSF NfL and clinical outcomes in 
dementia 
 
 
eurofilament light has been described as a biomarker of 
general neurodegeneration, specifically reflecting damage to 
white matter structures, rich in myelinated axons where NfL 
is abundant [258]. Paper II aimed to test this characterization by 
comparing CSF NfL concentrations in the most common dementia 
disorders. As in study I, clinical routine measurements of NfL from the 
Sahlgrenska University hospital was collected and clinical information on 
all subjects was brought in from Svedem. However, in this study 
mortality information from the Swedish mortality registry was also linked 
in. The resulting dataset contained 3356 individuals in 10 different 
diagnostic groups (early onset AD [EAD], LAD, FTD, DLB, VaD, 
PDD, mixed AD/vascular dementia, dementia not otherwise specified, 
other dementias and healthy controls), whereof 478 had a registered date 
of death. 
 The highest CSF NfL concentrations were found in FTD, VaD 
and mixed AD and vascular dementia. This is in keeping with the idea of 
NfL as a biomarker of white matter loss as these diseases all cause 
damage to regions of the brain rich in myelinated axons. EAD had low 
N
concentrations in parity with healthy controls, while LAD patients had 
higher concentrations. The explanation for this could be that EAD 
patients are known to exhibit more clear AD pathology, while LAD 
patients often exhibit concomitant pathologies and vascular components. 
 In LAD and mixed AD and vascular dementia we could also 
identify correlations between high CSF NfL concentrations and disease 
progress with MMSE scores as a proxy, which also ties into the role of 
NfL as a correlate for ongoing neurodegeneration. The MMSE test is 
designed to specifically measure hippocampal function, which might 
explain the lack of correlation in non-AD-dementias. We could however 
detect a universal association of shorter survival time and higher NfL 
CSF concentrations. This was true in both patients with AD-like and 
non-AD-like biomarker patterns of Aβ1-42, T-tau and P-tau. These 
properties solidify the role of CSF NfL as a biomarker of general rate of 
neurodegeneration, and not a biomarker reflecting a disease specific 
pathologic mechanism or process. It also highlights the suitability of CSF 
NfL as an outcome marker in clinical trials of drugs aiming to limit or 
stop neurodegeneration, not only in AD but across the dementia 
spectrum. 
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Paper III – CSF Tau in CJD 
 
 
eutzfeldt-Jakob disease is the most aggressive 
neurodegenerative disease known, with time of survival from 
diagnosis seldom surpassing a year. Despite the fast 
progression, it can often be hard to clinically diagnose CJD and post-
mortem analysis of the brain is still the gold standard for a definitive 
diagnosis. CJD further stands out from the crowd of neurodegenerative 
diseases in that it is transmittable, and by that important to correctly 
identify. CSF T-tau concentrations have in previous studies been shown 
to be markedly elevated in CJD [259-261]. In study III we gathered 
clinical routine CSF T-tau and P-tau measurements from the lab database 
at the Sahlgrenska university hospital and brought in clinical and 
mortality data from the Swedish mortality registry. Information on 9765 
individual patients was collected, including 93 with CJD. 
 We could confirm that CJD patients exhibit considerably higher 
concentrations of CSF T-tau, as the CJD patients in our cohort had both 
mean and median levels of T-tau at more than 10-15 times those of non-
CJD patients. However, P-tau levels were not elevated in the CJD 
patients, corroborating the specificity of P-tau for AD pathology.  
C 
 Using the T-tau concentrations and T-tau/P-tau ratios of the 
patients in the study cohort, ROC analysis could discriminate CJD 
patients from controls and patients with AD and other dementias with 
very high performance (AUCs ranged from 0.949 - 0.984). The ROC 
analysis was calculated using the first biomarker measurement for those 
of the included patients with consecutive measurements. When relating 
T-tau concentrations to time of survival in our cohort a clear trend of 
rapidly rising T-tau concentrations closer to date of death could be seen 
(figure 10).  On further inspection, the same phenomenon could be seen 
in the sub-sample of patients in our cohort with repeated CSF T-tau 
measurements. In this group an exponential increase in T-tau 
concentrations could be observed as time to death diminished (figure 
11). This trend could not be observed in patients with AD or other 
dementias where both T-tau and P-tau concentrations remained stable in 
relation to survival. 
 
Figure 10. T-tau concentrations exponentially increase as date 
of death approaches. 
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Figure 11. The longitudinal measurements of CSF T-tau in CJD reveal an exponential increase as 
date of death approaches. 
 
This study demonstrates the diagnostic power of T-tau and the 
T-tau/P-tau ratio in CJD. It also highlights the violent nature of CJD 
through the unparalleled rise in T-tau concentrations as the disease 
progresses. This property has not been demonstrated through 
longitudinal data before and is most probably unique to CJD pathology, 
and might be utilized in the diagnostic process. A suspected but not 
verified case of CJD could or should be examined again to check for 
increased T-tau concentrations strengthening the diagnostic assessment.  
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Paper IV – Hypothesis generation with 
clustering in peptidomics and identification of 
PTN151-166 as a biomarker of AD. 
 
 
n paper IV we set aside prevailing paradigms in AD pathology 
theory, setting out to find new biomarker prospects and generate 
new hypotheses to hopefully further the field and deepen the 
understanding of AD pathology. To achieve this we developed a new 
way of analyzing the vast amount of data generated in TMT LC-MS/MS 
analysis of CSF samples. By applying this new strategy of analysis, we 
were able to mine valuable information from sections of data that would 
be discarded in conventional analysis work flows.  
To organize and make sense of the massive data output from TMT 
LC-MS/MS analysis, the generated data, basically consisting of gigabytes 
of lists of detected peptides, their precursor m/z and the peptide 
spectrum produced at fragmentation, is matched against protein 
sequence databases of known peptides and accompanying fragment 
spectra. Identification is achieved by utilizing the combination of the 
precursor m/z and the fragment spectra as a unique fingerprint and key 
to identification [262]. These databases work well in identifying tryptic 
peptides, where about 90% of detected peptides can usually be identified. 
I
However, the databases are far less complete when it comes to 
endogenous peptides. In an average endogenous peptide dataset about 
20-30% of peptides are identified. Another limitation of trypsination is 
that the enzyme digestion discards valuable information. Trypsin cleaves 
peptide chains at lysine or arginine, thus proteins and peptides rich in 
those amino acids might get chopped up into parts too small for 
identification, permanently obscuring parts of the proteome [263]. 
Further, the proteome is accompanied by a peptidome, i.e. naturally 
occurring protein fragments that are part biologically inactive traces of 
degradation of proteins, but also contain bioactive species that interact 
with receptors, transmitting, modulating or counteracting responses [264, 
265]. After trypsination, information on naturally occurring peptides and 
forms of proteins is partly lost, since it’s not always possible to determine 
if a peptide is naturally present in the peptidome or the result of 
enzymatic cleavage by trypsin. The peptidome is important. Examples of 
important bioactive endogenous peptides include: 
 Substance P, a neuropeptide that interacts with the neurokinin 
1 receptor and mediates vasodilation, inflammation and pain 
[266]. 
 Angiotensin I and II, peptide hormones that are involved in 
vasoconstriction and increased blood pressure through the 
renin-angiotensin system [267]. 
 Neuropeptide Y, a neuropeptide with several functions that is 
active both in the CNS and the peripheral nervous system. It is 
considered stress-relieving, anxiolytic and neuroprotective [268]. 
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There is also value in exploring the biologically inactive remains of 
protein degradation, as they might be traces and biomarkers of important 
upstream processes. A prominent example of this is Aβ1-42 [269]. 
Exploration of the peptidome is prohibited by pre-analytical digestion as 
there is no way of discerning what peptides have been cut by artificial 
means or not.  
In paper IV, we aimed to circumvent the limitations of 
trypsination and database searching and rearranged the work flow, 
skipping the database search and replacing it with a spectral clustering 
step. The spectral clustering uses an algorithm to sift through the data, 
clustering together spectra based on precursor m/z, charge state and 
fragment ion patterns [270]. The relative abundance of the peptides in 
the resulting clusters can then be mapped against individual patient 
samples by means of the TMT reporter ions. The resulting array of 
clusters can thus be used to identify potential biomarkers by quantifying 
the relative concentrations of the clustered peptide in healthy controls vs 
disease groups, and evaluating their performance in separating the 
groups of interest. When a biomarker candidate is identified, it is then a 
matter of manual labor to identify the peptide sequence. By this strategy 
we managed to tap into the unexplored realms of the endogenous 
peptidome in a discovery cohort consisting of 40 healthy controls, 40 
MCI patients and 40 patients with AD from the Amsterdam Dementia 
Cohort [271].   
The clustering algorithm generated a list of 220,869 clusters. The 
clusters where a quantifiable signal was detected for more than half of 
the patients in the study were selected and then subjected to individual 
ROC analysis. The AUCs of each cluster were then used to rank all 
clusters according to their performance in separating the AD patients 
from the healthy controls in our cohort. The top 20 clusters are detailed 
in table 1.  
Table 1. The top twenty clusters in the discovery set, ranked from their ability to separate 
patients with AD from cognitively normal controls using ROC analysis. 
Column descriptions from left to right: Cluster # (identifier); precursor m/z; detected charge-
state; the number of study subjects in which the cluster was quantified; the relative median 
difference in abundance between AD patients and cognitively healthy controls; calculated AUC 
(from ROC analysis); indication of successful identification of peptide sequence; the identified 
peptides’ protein of origin where applicable. 
Cluster 
# 
m/z Charge Subjects 
(n) 
Rel. diff. 
AD vs HC 
AUC - HC 
vs AD 
Peptide 
identified 
Protein 
affiliation 
7367 794.115 5 119 215%** 0.96* -  69078 664.799 2 94 18%** 0.92* -  32527 777.426 3 68 13%** 0.92* -  78065 748.382 2 120 38%** 0.91* √ Osteopontin 
4243 696.457 5 59 103%* 0.91* -  82223 794.885 2 111 28%** 0.90* √ Clusterin 
34935 810.044 3 58 16%** 0.9* -  9084 836.597 5 86 47%** 0.87* -  36033 823.45 3 120 18%** 0.87* √ ApoE 
61266 1380.71 3 70 -20%** 0.86* -  1889 427.579 3 120 15%** 0.86* -  33238 787.612 3 69 19%** 0.85* -  25327 684.044 3 60 9%** 0.85* -  13290 840.651 4 111 17%** 0.85* √ Secretogranin1 
10464 786.901 4 59 22%** 0.85 -  71623 685.336 2 61 13%** 0.83* -  12243 911.104 5 70 -28%** 0.82 -  87816 848.511 2 69 16%** 0.8* -  6405 690.794 4 60 13%* 0.79* -  53204 1088.54 3 60 4%* 0.79* -  
 
** Indicates statistical significance (p < .001) 
* Indicates statistical significance (p < .05) 
 
 Cluster 7376 exhibited promising qualities as a biomarker 
candidate with an AUC of 0.96, i.e. a near perfect discrimination of AD 
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patients and controls, and a relative median abundance difference of 
215% between the same groups. On further inspection the peptide 
revealed more 
interesting properties.  
The relative abundance 
of cluster 7376 in the 
MCI patients was at 
intermediate levels 
between the controls 
and the AD patients, 
further indicating a 
relation to AD 
pathology. Further, the 
MCI patients who at 
follow-up had 
progressed to AD (MCI-AD) had high abundances, reaching for the 
same as the AD patients, while the patients who remained at the MCI-
stage at follow-up (MCI-S) had abundances comparable to the healthy 
controls (figure 12). This is a sought after feature in an AD biomarker as 
being able to distinguish the MCI-S from the MCI-AD patients is 
important but can be clinically challenging. Even further, the MCI 
patients who progressed to other dementia disorders exhibited low 
abundances of the cluster 7376 peptide, with a mean level 35% higher 
than the healthy controls and 50% lower than the MCI patients that 
progressed to AD. Although the number of patients in this group was 
very limited (n=4), this hints at a specificity for detecting AD pathology. 
Another positive finding when studying the details in the properties of 
Figure 12. Scatter plot of the relative abundances of cluster 7376 
in the sub groups of the study cohort.
cluster 7376 was that the few MCI-S patients who had high abundances 
of the cluster 7376 peptide tended to be amyloid positive, indicating a 
high risk of developing AD [272]. All in all, cluster 7376 exhibited ideal 
properties for an AD biomarker and was selected as the first candidate 
for further analysis.  
The identity of the cluster 7376 peptide proved elusive. The 
sleuth-like process of deconvoluting the peptide sequence from a 
fragment pattern and the m/z,  de novo sequencing, requires input in the 
form of an as rich fragment pattern as possible [273]. The original 
fragment pattern of cluster 7376 revealed little information, and when 
increasing the collision energy to crack more peptide bonds, the whole 
peptide seemed to obliterate, leaving no traces to aid the identification 
process. The key eventually turned out to be to switch fragmentation 
method. The Thermo Fusion mass spectrometer used in this study 
allows for not only the standard higher-collisional energy dissociation 
(HCD) fragmentation technique, but also electron transfer dissociation 
(ETD) fragmentation that is particularly well suited for fragmenting 
peptides with charge states >2 (the cluster 7376 peptide had a charge 
state of 5). The peptide sequence of cluster 7376 was revealed as 
AESKKKKKEGKKQEKM, and identified as amino acids 151-166 
from the sequence of the protein pleiotrophin (PTN). PTN is described 
in the literature as being abundant in the hippocampus and entorhinal 
cortex, but with no specific link to AD [208, 209]. PTN is covered in 
detail in the CSF biomarkers chapter of this thesis.  
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After candidate 
selection and identification, 
PTN was validated in an 
independent secondary 
patient cohort, consisting 
of 15 healthy controls and 
15 of each of AD, PD and 
PSP patients. A targeted 
Orbitrap parallel reaction 
monitoring (PRM) approach was used for analysis. The AD patients 
were verified as having a higher abundance of PTN151-165 compared to 
controls, and the specificity for AD-pathology was further corroborated 
as the PD and PSP patients were indistinguishable from the healthy 
controls (figure 13).  
This study serves as a proof-of-concept of the utility of the novel 
spectral clustering work-flow as a hypothesis generating machine. It 
should be noted that the clustering algorithm used in this study was not 
specifically designed for this task and could likely be improved to better 
performance. It should further be noted that out of the twenty top 
biomarker candidates that emerged in the discovery cohort, only four 
were readily identifiable. Several tantalizing candidates still remain to be 
processed. For instance, cluster 4243 had an AUC of .91 and a relative 
abundance median difference of 103%. The identity of this peptide still 
remains to be discovered. The developed spectral clustering work-flow 
has yet to be applied to one large cohort, but is universally applicable to 
MS/MS data and has tremendous potential to reveal further secrets in 
Figure 13. Scatter plot of the relative abundances of 
PTN151-166 in the validation cohort- 
other disease groups, fluids (plasma? saliva? urine?) and in variations of 
pre analytical processing of samples and mass spectrometer settings. 
PTN151-166 is a promising biomarker candidate. The PRM method 
used in the validation cohort is not ideal for systematic PTN151-166 
assessment, but the development of a targeted assay has not yet 
succeeded. The unusual nature of PTN151-166 in terms of extreme 
hydrophobicity and charge to mass ratio has proven hard to overcome 
hurdles in the method development. However, a targeted method will 
likely improve the diagnostic performance of PTN151-166. When a targeted 
method is finalized, the doors are open for further studies to proceed in 
characterizing the relation and specificity of PTN151-166 to AD-pathology, 
its potential in AD staging, and its relation to other biomarkers of AD 
and neurodegeneration. Hopefully, apart from providing clues to the 
inner workings of AD pathology, PTN151-166 can add another tool to the 
AD biomarker toolbox complementary to Aβ1-42, T-tau, P-tau, Ng and 
NfL. Potential functions of PTN151-166 that need to be examined and that 
PTN151-166 might add include earlier, more specific and more reliable 
diagnostics, sub classification of AD pathology or dependable 
assessment of rate of on-going pathology.  
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Discussion 
 
 
he growing threat of dementia to global health has motivated 
extraordinary efforts to be put into research to understand the 
many facets of neurodegeneration and to find effective 
treatments. Despite these efforts several key issues remain to be resolved 
and no disease modifying treatments have been found. CSF biomarkers 
have several different applications in dementia research and can in 
several different ways be used to forward the field. The papers included 
in this thesis highlight several of them.  
 The results in paper I validate the value of the core AD 
biomarkers, Aβ1-42, T-tau and P-tau, in discriminating AD from other 
dementias. It also demonstrates the lack of clear clinical and pathological 
syndromes in dementia in the large amount of overlap and spread in 
biomarker concentrations between the clinical diagnoses, indicating and 
corroborating what many previous studies have shown, i.e. that presence 
of concomitant AD-like pathology is common in other dementias. The 
inverse is also true in many cases. It might even in some settings be more 
T 
appropriate to consider dementia as a spectrum of clinical phenotypes 
exhibiting symptoms of degeneration stemming from a set of 
pathological concomitant and often related processes. There is an 
important difference in the clinical phenotype and the neuropathological 
correlate. The complex relationships between clinical presentations and 
immunohistochemical classifications in FTLD and FTD demonstrate 
this. FTD patients often suffer from frontotemporal tau or TDP-43 
pathology, but TDP-43 aggregates can also be seen in MND, although in 
different anatomical regions. FTD is in itself an array of similar disorders 
with different clinical presentations dependent on varying anatomical 
focal points of neurodegeneration and varying degrees of influences of 
tau and TDP-43 aggregation. Tau pathology is also present in AD, but in 
different anatomical regions of the brain, and with different influence of 
tau isoforms. And further, TDP-43 pathology is present in as many as 
40% of AD patients, but in the hippocampus and the entorhinal cortex, 
as opposed to in the frontal regions in FTD. Aβ plaque accumulation is a 
hallmark feature of AD but can also be seen in abundance in DLB, a 
disorder that is recognized neuropathologically by a build-up of α-
synuclein containing Lewy bodies in the cortex and substantia nigra. And 
inversely, Lewy bodies are found in more than half of the brains of AD 
patients’ post-mortem. Further, DLB doesn’t differ from PDD in 
neuropathological terms, but are only distinguished in clinical 
presentations where parkinsonian symptoms precede dementia in PDD 
while the order is reversed in DLB. Effects of vascular pathology is also 
very common in the elderly and might in addition to the mentioned 
disease processes further color the clinical presentation and affect the 
neurodegenerative processes. A drug trial might thus benefit from 
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assessing not only signs of the particular disease that it is aimed to treat, 
but also amounts of concomitant neuropathological processes that might 
influence the clinical phenotype and outcome measures of the trial. 
Treatments could be considered to target pathological processes rather 
that dementia syndromes. Awareness of the intertwined nature of the 
pathological processes in dementia should also be taken into account in 
studies aiming to explore the underlying causes of neurodegenerative 
diseases. Well-characterized biomarkers could help identify and quantify 
influences of different pathological processes in a patient and to tailor 
future treatments based on that information. 
 
Figure 14. Venn diagram of related pathologies in Dementia. 
Well characterized biomarkers play important roles in drug trials, 
where a prerequisite to produce dependable results is to enroll well suited 
subjects. There are several challenges in this task. Timing is of the 
essence as the neurodegenerative aspects of AD and other dementia 
disorders lead to neuronal damage that is likely irreversible, making it 
urgent to stop disease processes before damage sufficient to render 
clinical symptoms have occurred. CSF biomarkers can help identify 
subjects in the subclinical stages of disease that are more likely to be 
eligible for treatment. Having pathological concentrations of the 
biomarkers covered in paper I, i.e. CSF Aβ1-42, T-tau or P-tau, while at 
the MCI stage has been shown to be associated with a heightened risk of 
developing AD [274]. CSF NfL concentrations have also been shown to 
predict a more rapid decline from MCI at baseline into dementia [275]. 
CSF concentrations of PTN, the candidate biomarker identified in paper 
IV, were markedly elevated in AD, but also in MCI patients that on 
follow-up progressed to AD and in MCI patients that on follow-up had 
not yet progressed but were Aβ-positive, i.e. likely to progress to AD at a 
later point in time [276]. These properties would be ideal to help identify 
MCI patients likely to progress to AD, but need to be validated in further 
studies. 
Another reason for the importance of timely administration of 
treatment could be that hindering an upstream event might be necessary 
to be able to stop the disease progression in dementia, again highlighting 
the need for early biomarkers. In CJD, prions propagate their destructive 
properties from cell to cell in an ever multiplying fashion. 
Neurodegeneration escalates at an exponential rate as demonstrated in 
paper III by the marked increases in T-tau as the affected patient 
approach death. A single unfortunate event in the misfolding of a PrP-
protein might be sufficient to spark this process, but a single misfolded 
PrP-protein left behind after a nearly complete PrPSc-eradication by a 
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fictional future drug might also re-ignite it. As previously discussed, 
evidence suggests that tau and Aβ-pathology might also propagate in a 
prion-like fashion. This might be one of the reasons drug trials in AD in 
humans have thus far been futile.  
Another important aspect of successful drug trials and feature of 
well-researched biomarkers is to properly assess the effects of the given 
treatment. In dementia, stopping neurodegenerative processes is a core 
focus and means to measure the dynamics of these processes is needed 
to set up a primary outcome. In paper II, CSF NfL was shown to be 
increased in several dementias and to be correlated to cognitive 
performance and survival time. Several other studies have also provided 
evidence for CSF NfL as a measure of on-going neurodegeneration, 
particularly in subcortical regions of the brain [258]. These properties 
make NfL a suitable primary outcome measure in drug trials in 
neurodegenerative disorders, including AD, vascular dementia and FTD. 
In paper III, the CSF T-tau concentrations in CJD patients were 
observed to increase with disease burden and in relation to survival. T-
tau could thus be a suitable candidate marker for the monitoring of 
disease modifying treatments in CJD.  
The lack of positive results in AD drug trials indicates that the 
amyloid cascade hypothesis has limitations. The BACE1-inhibitor 
Verubecestat was developed by Merck and showed promising results in 
phase 1/2 studies with CSF Aβ concentrations in treated patients 
reduced by as much as 90 %, and no serious adverse effects. However, 
the following phase 2/3 EPOCH study had to be aborted in February of 
2018 when it was discovered in an interim analysis that treated patients 
performed worse than the placebo group in CDR-SB and ADAS-Cog13 
[277]. Similar results came of the ELAN/Wyeth active vaccine trial 
where plaque removal was found at autopsy, despite continued clinical 
cognitive decline [278].  It might be that some unknown event or series 
of events lead up to the evolution of a self-replicating disease process, 
that can withstand targeting by, for instance, BACE1-inhibitors by no 
longer being dependent on Aβ1-42 shedding to advance. Another 
explanation for the failure of Aβ-targeting drugs could be that Aβ-
deposition is not the culprit in AD pathogenesis but merely a side-effect 
of other processes that cause neurodegeneration, or that Aβ is a 
physiological response to some other unknown pathological process 
[279]. Transgenic mice engineered to produce excess amounts of Aβ not 
generated from APP form Aβ plaques but exhibit no cognitive decline 
[280]. The Arctic familial mutation in APP lead to ADAD through more 
aggregation prone Aβ but does not show amyloid on PET, although 
diffuse plaques are present histopathologically, pointing to other forms 
of Aβ such as oligomers being important for the pathological processes 
in AD [281]. It has been pointed out that Aβ1-42 production always 
generate a complementary APP-product, the APP intracellular domain 
(AICD). Being intracellular, the AICD is better situated to instigate cell 
damage than Aβ plaques [282]. The AICD has, however, not yet been 
thoroughly investigated. Aβ, or some form of Aβ, might even be a 
protective agent, which would explain why the Verubecestat treated 
patients had a faster rate of progression than the placebo group. In any 
case, this highlights the need to further detail the pathological 
mechanisms in AD and dementia in general. 
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To deepen the understanding of the molecular processes leading 
up to the pathologies present in dementia, innovative and explorative 
studies are needed. Efficient hypothesis generation and testing, as 
demonstrated in paper IV of this thesis, might be an important tool to 
uncover missing links, unravel the complex biochemical pathways in 
dementia and to guide further studies into uncharted territory. In paper 
IV, a vast amount of peptides were found and tested for their properties 
as biomarkers of AD. It should be noted that only five of those 
promising biomarkers were sequenced and one chosen for further 
processing and validation. 15 more biomarkers that all separated AD 
from controls with an AUC of >0.75 and with p-values < .05 were left 
untouched. We recognize the problem of multiple testing in studies like 
this, but through further validation the false positives would readily be 
discovered. Further effort put into automatization and fine-tuning of the 
clustering, as well as the selection and identification processes would 
likely maximize output and limit the amount of manual labor needed to 
run further studies applying the spectral clustering work-flow described 
in paper IV.  
The neurodegeneration biomarker toolbox 
 The results of paper I-III of this thesis demonstrate the power of 
carefully mapping out the properties of biomarkers across and between 
disorders and stages of disease. By rigorous characterization of 
biomarkers by the many research groups in the field, a biomarker 
toolbox has been created, containing gear to address a plethora of 
important questions that arise in relation to neurodegeneration in both 
the clinical and research settings. Aβ1-42, T-tau and P-tau, can be used to 
identify AD pathology even at very early and preclinical stages of disease, 
providing insights into the pathological processes underlying the disease 
(figure 14). Being able to reliably identify the most common dementia 
disorder and discriminate it from important differential diagnoses aids 
the diagnostic process of dementia. CSF Aβ1-42, t-tau and p-tau might 
further be used to assess the efficacy of potential treatments of AD.  
 As demonstrated in paper III, T-tau, but not P-tau, is also a 
biomarker of CJD where even higher concentrations than in AD can be 
seen. A pattern of ever increasing concentrations is also a hallmark CJD 
sign, not seen in other diseases.  
 NfL can be used to assess rate of ongoing subcortical 
neurodegeneration across several dementias, and might be considered a 
biomarker of general neurodegeneration. It is also associated with 
survival, in that higher concentrations are linked to shorter life 
expectancy in AD, but also other dementias. Particularly high CSF NfL 
concentrations are seen in FTD that engage the frontal cortex, which is 
rich in myelinated axons, and can be used to strengthen the case for 
FTD in differential diagnostic inquiries. 
 PTN151-166, the new biomarker prospect identified in paper IV, is 
naturally a lot less well characterized than the other biomarkers described 
in this thesis. However, it has showed promising properties so far. The 
MCI patients in the discovery set had higher levels of PTN151-166 than the 
healthy controls, and at follow-up, the MCI patients with higher 
concentrations at baseline had more often progressed to AD than those 
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with low concentrations. As previously discussed, this is a central feature 
of any AD biomarker. Further studies are needed to more carefully 
establish at what stage of disease concentrations of PTN151-166 might start 
to change, and to relate these changes to detectable changes in other 
biomarkers and cognition, i.e. to fit it into the Jack-curve (figure 15). 
Further studies are also needed to identify the pathological significance 
of PTN151-166 to AD pathology, and its relation to disease processes in 
other diseases. 
 
 
These are only the CSF biomarkers covered in this thesis. Many 
other imaging and fluid biomarkers exist that all add utility to the 
biomarker toolbox. However, and as previously discussed, the need to 
further expand this toolbox is still high. No cure for any dementia yet 
exists, and proper equipment to tackle the task of finding one is in 
demand. 
 
Figure 15. The Jack-curve. A popular model of the order of events in 
AD. Image courtesy of Clifford Jack and Lancet Neurology. 
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Concluding remarks and outlook 
 
he findings presented in the studies of this thesis demonstrate 
the value of CSF biomarkers from several aspects. The 
diagnostic value of CSF biomarkers is shown in paper I, III 
and IV where AD and CJD were discriminated from healthy controls 
and important differential diagnoses with high accuracy. The prognostic 
value of CSF biomarkers were displayed in paper I, II, III and IV where 
clinical outcomes measured by conversion from MCI to AD, cognitive 
test scoring and time of survival where predicted. The investigative value 
of a CSF biomarker was exhibited in paper IV, where a peptide was 
shown to have a previously unknown association with AD pathology, 
leaving further investigation into the implications of this relationship to 
be addressed by further studies.  
 The hunt for disease modifying treatments of neurodegenerative 
diseases is on. While no clinical trials have been fruitful in recent years, 
many are sure still to come. All major experimental drugs tested in these 
clinical trials have been developed in models of ADAD, i.e. not in SAD, 
the most prominent and common type of the disease, and not the one 
that these drugs have been subjected to treat. This design flaw will 
T 
probably have to be remedied in future trials. Biomarkers will continue 
to aid these trials in patient recruitment and assessment of effectiveness. 
Hopefully, successful trials will soon yield effective treatments, and when 
that goal is reached, biomarkers will likely be needed to continuously 
identify patients eligible for treatment. Future studies into blood 
biomarkers will likely widen the scope of use of biomarkers in 
neurodegeneration.  
 Some tools are still missing in the biomarker toolbox. No 
effective biomarkers of PD or PDD exist today. A way of assessing α-
synuclein pathology would aid a difficult diagnostic process, which is 
today based on the clinical features of the patient, and would benefit 
patients, doctors and researchers alike. The same would be true of a 
biomarker of TDP-43 pathology in FTD, and different types of tau 
pathology in tauopathies. 
 The continued failure of drugs targeting the usual suspects as 
stated by the amyloid cascade hypothesis emphasizes the value in 
keeping an open mind to revising the model and to find new drug 
targets. Explorative studies like the one in paper IV might aid this 
process. Most certainly, there are still secrets to unveil that will shed light 
onto the inner workings of the pathologic processes in AD. 
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